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Abbreviations and Acronyms
AR ¼ aortic regurgitation
AS ¼ aortic stenosis
AVA ¼ aortic valve area
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This document has been developed as an Expert Consensus
Document (ECD) by the American College of Cardiology
Foundation (ACCF), American Association for Thoracic
Surgery (AATS), Society for Cardiovascular Angiography
and Interventions, and the Society of Thoracic Surgeons in
collaboration with the American Heart Association (AHA),
American Society of Echocardiography, European Associa-
tion for Cardio-Thoracic Surgery, Heart Failure Society of
America, Society of Cardiovascular Computed Tomography,
Society of Cardiac Magnetic Resonance, Society of Cardio-
vascularAnesthesiologists, andMendedHearts. ECDsare in-
tended to inform practitioners, payers, and other interested
parties of the opinion of ACCF and document cosponsors
concerning evolving areas of clinical practice and/or technol-
ogies that may bewidely available ormay be new to the prac-
tice community. Topics chosen for coverage by ECDs are so
designed because the evidence base, the experience with
technology, and/or clinical practice are not considered suffi-
ciently well developed to be evaluated by the formal ACCF/
AHA Practice Guidelines process. Often the topic is the sub-
ject of considerable ongoing investigation. Thus, the reader
should view the ECD as the best attempt of the ACCF and
document cosponsors to inform and guide clinical practice
in areas where rigorous evidence may not yet be available
or evidence to date is not widely applied to clinical practice.
When feasible, ECDs include indications or contraindica-
tions. Some topics covered by ECDswill be addressed subse-
quently by the ACCF/AHA Practice Guidelines Committee.
To avoid actual, potential, or perceived conflicts of inter-
est that may arise as a result of industry relationships or per-
sonal interests among the writing committee, all members
of the writing committee, as well as peer reviewers of the
document, are asked to disclose all current health care–
related relationships, including those existing 12 months
before initiation of the writing effort. The ACCF Task Force
on Clinical Expert Consensus Documents (TF CECD) re-
views these disclosures to determine what companies
make products (on market or in development) that pertain
to the document under development. Based on this informa-
tion, a writing committee is formed to include a majority ofrdiovascular Surgery c Volume 144, Number 3 e31
Clinical Guidelines Holmes et almembers with no relevant relationships with industry or
other entity (RWI), led by a chair with no relevant RWI.
Authors with relevant RWI are not permitted to draft
or vote on text or recommendations pertaining to their
RWI. RWI is reviewed on all conference calls and updated
as changes occur. Author and peer reviewer RWI
pertinent to this document are disclosed in Appendices 1
and 2, respectively. Additionally, to ensure complete
transparency, authors’ comprehensive health care–related
disclosure information—including RWI not pertinent to
this document—is available online (see Online Appendix
3). Disclosure information for the ACCF TF CECD is
also available online at www.cardiosource.org/ACC/
About-ACC/Leadership/Guidelines-and-Documents-Task-
Forces.aspx, as well as the ACCF disclosure policy for
document development at www.cardiosource.org/Science-
And-Quality/Practice-Guidelines-and-Quality-Standards/
Relationships-With-Industry-Policy.aspx.
The work of the writing committee was supported exclu-
sively by the ACCF without commercial support. Writing
committee members volunteered their time to this effort.
Conference calls of the writing committee were confidential
and attended only by committee members.
Robert A. Harrington, MD, FACC
Chair, ACCF Task Force on Clinical Expert Consensus
Documents1. INTRODUCTION
1.1. Document Development Process
1.1.1. Writing Committee Organization
The Writing Committee consisted of a broad range of
members representing 12 societies and the following
areas of expertise: cardiothoracic surgery, interventional
cardiology, general cardiology, geriatric cardiology, echo-
cardiography, cardiac anesthesiology, cardiac computed to-
mography (CT), cardiac magnetic resonance (CMR),
cardiac nursing, heart failure, neurology, valvular heart dis-
ease, structural heart disease, and the consumer perspective.
Geographic distribution of members crossed most U.S. time
zones and included international representation. Members
with expertise using this new and emerging technology
and those with expertise in their content area, but not in
the procedure discussed herein, served on the committee
to provide appropriate balance of perspectives.
This writing committee met the College’s disclosure re-
quirements for relationships with industry as described in
the Preamble. Important to note, if an author works in an in-
stitution that serves as a TAVR trial site but has no direct re-
lationship with the trial sponsor or other relevant company
(that produces [competing] products or services discussed
in this document) or institutional relationship as defined
by the ACCF Disclosure Policy for Documente32 The Journal of Thoracic and Cardiovascular SurgDevelopment, the trial site information was not deemed rel-
evant to this writing effort and is not included in the table of
relevant author disclosures (Appendix 1). For example, if an
author works in an institution where TAVR is performed,
but he/she: (1) does not personally perform the procedure;
or (2) performs the procedure but has no direct relationship
to the trial (eg, principal investigator, investigator, steering
committee member, consultant) and does not oversee funds
related to the trial, then the relationship is not included in
the table of relevant disclosures. In these situations, these
relationships do not even need to be disclosed. However,
in the spirit of full disclosure, this information is recorded
in the online disclosure table containing all author health
care relationships.1.1.2. Document Development and Approval
TheWriting Committee convened by conference call and
e-mail to finalize the document outline, develop the initial
draft, revise the draft per committee feedback, and ulti-
mately sign off on the document for external peer review.
All participating organizations participated in peer review,
resulting in 48 reviewers representing 1087 comments.
Comments were reviewed and addressed by the writing
committee. A member of the ACCF TF CECD served as
lead reviewer to ensure that all comments were addressed
adequately. Both the Writing Committee and TF CECD ap-
proved the final document to be sent for board review. The
ACCF Board of Trustees, AATS Council, SCAI Board of
Directors, and STS Board of Directors reviewed the docu-
ment, including all peer review comments and Writing
Committee responses, and approved the document in Janu-
ary 2012. The AHA, ASE, EACTS, HFSA, Mended Hearts,
SCA, SCCT, and SCMR endorsed the document in January
2012. This document is considered current until the TF
CECD revises or withdraws it from publication.1.2. Purpose of This Document
Transcatheter aortic valve replacement (TAVR) offers
new and potentially transformational technology for pa-
tients with severe aortic valvular stenosis who are either ex-
tremely high-risk candidates or inoperable for surgical
aortic valve replacement (AVR) or who are inoperable by
virtue of associated comorbidities. In the future, this tech-
nology may be utilized in lower risk surgical candidates.
An estimated 40,000 patients have received TAVR world-
wide.Multiple single andmulticenter registries, and a single
randomized trial, have documented favorable outcomes
using a wide spectrum of endpoints, including survival,
symptom status, quality of life, and need for repeat hospital-
ization. The implementation of TAVR into the flow of pa-
tient care is complex, involving consideration of several
key factors such as clinical site selection, operator and
team training and experience, patient selection andery c September 2012
Holmes et al Clinical Guidelinesevaluation, procedural performance and complication man-
agement, and postprocedural care. Collaborative stake-
holder involvement is required in the management of this
high-risk patient population with extensive coexistent med-
ical conditions. A previously published document by ACCF
and STS identified a high-level series of issues to be ad-
dressed regarding this technology.1 This current collabora-
tive expert consensus document, which involves 12
professional societies, addresses these issues in greater de-
tail with the intent to examine the current state of the evi-
dence, facilitate the integration of this technology into the
armamentarium of therapeutic options for patients with aor-
tic valvular stenosis, and to enable responsible adoption and
diffusion of this promising technology. This document has
focused on published data; it must be remembered that there
is only 1 single completed randomized trial, although others
are in progress or planned; much of the data in this expert
consensus document is based upon information from stud-
ies and registries, both surgical and TAVR, which are fre-
quently retrospective and include self-reported clinical
events rather than adjudicated events.
2. BACKGROUND AND HISTORICAL ASPECTS
The most common cause of valvular aortic stenosis (AS)
in adults is calcification of a normal trileaflet or congenital
bicuspid valve.2-4 Calcific AS is characterized by lipid
accumulation, inflammation, fibrosis, and calcification5,6
and is common in the United States. It typically presents
in older individuals (ie,>75 years) in contrast to bicuspid
AS, which presents a decade or more earlier. Rheumatic
AS, uncommon in the Western world, occurs due to
fusion of the commissures with scarring and calcification
of the cusps, and retraction of the leaflets resulting in the
valve being both regurgitant and stenotic.
2.1. Pathophysiology and Clinical Course
In adults with valvular AS, the obstruction develops grad-
ually, typically overmany years duringwhich the left ventri-
cle (LV) adapts to the systolic pressure overload with
progressive concentric hypertrophy that results in diastolic
dysfunction,4,7,8 reduced coronary reserve,9,10 myocardial
ischemia,11 and eventually, depressed contractility resulting
in LV systolic dysfunction.12-14Ultimately, in some patients,
heart failure or sudden death occurs. Typically, patients with
AS are free from cardiovascular symptoms (ie, angina,
syncope, and heart failure) until late in the course of the
disease. However, once symptoms manifest, the prognosis
is poor, with the interval from the onset of symptoms to
the time of death being approximately 2 years in patients
with heart failure, 3 years in those with syncope, and
5 years in those with angina.15 Gardin et al. reported that
among symptomatic patients with moderate-to-severe AS
treated medically, mortality rates after the onset ofThe Journal of Thoracic and Casymptoms were approximately 25% at 1 year and 50% at
2 years,16 with approximately 50% of deaths being sudden.
In the elderly high-risk patients in the PARTNER (Place-
ment of Aortic Transcatheter Valve) trial who were treated
medically (Cohort B), the survival at 1 year was only 50%.15
The natural history of AS has changed since the publica-
tion of the seminal paper by Morrow and colleagues in
1968.17 The original data were derived largely from patients
with rheumatic AS or AS due to a bicuspid aortic valve,
with an average age of death of 63 years. On the contrary,
patients being considered for TAVR on a trileaflet valve
present much later in life, typically in their late 70s or older,
and have dominantly fibrocalcific AS. Although now occur-
ring later in life, the onset of symptoms still heralds a rapid
decline with medical therapy alone.15
2.2. Diagnosis
2.2.1. Echocardiography Versus Catheterization
Assessment of the severity of stenosis does not differ in
TAVR patients compared with the general AS population,
and decisions should therefore be based upon established
guidelines.18 Although invasive cardiac catheterization has
historically been the standard for quantification of AS, this
function has been largely replaced by echocardiography.19
Echocardiographic diagnosis is made by the observation
of a calcified valve with restricted leaflet opening by two-
dimensional (2D) echocardiography with quantification of
the peak and mean AV gradient made by applying the sim-
plified Bernoulli equation (Dp¼ 4v2) to the maximal veloc-
ity recorded through the aortic valve by continuous-wave
Doppler. Multiple imaging windows (apical 4-chamber
and long-axis, right parasternal, suprasternal notch, and
subcostal views) should be obtained to assure acquisition
of the maximal velocity and to avoid angle-related errors.
Although aortic valve area (AVA) can be measured by
planimetry, it is more accurately assessed by application
of the continuity equation, using pulsed-wave Doppler in
the left ventricular outflow tract (LVOT) and continuous-
wave Doppler across the valve. Severe stenosis is defined
in the guidelines as a peak velocity>4.0 m/s (corresponding
to a peak gradient of 64 mm Hg), a mean gradient>40 mm
Hg, OR valve area<1.0 cm2 when LV systolic function is
normal. To account for patient size, the valve area is often
indexed to body surface area, with 0.6 cm2/m2 considered
to be the threshold for severe AS. An important exception
is when the gradient suggests less severe stenosis than the
valve area, most commonly due to low stroke volume, either
in dilated ventricles with low ejection fraction (EF) or small
ventricles with normal EF. In this setting, a dobutamine
stress study (maximum stress dose 20 mcg/kg/min), may
be helpful. If the maximum jet velocity rises over 4 m/s
with the dobutamine-induced increase in stroke volume
whereas the AVA remains less than 1.0 cm2, then the valverdiovascular Surgery c Volume 144, Number 3 e33
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ume increases with little rise in gradient (causing valve
area to increase substantially), then the AS is only mild to
moderate in severity, and the LV dysfunction is due to
causes other than AS.20-22
Occasionally, the AVA appears larger than the elevated
gradient would suggest, usually due to elevated stroke vol-
ume from aortic regurgitation (AR), anemia, fever, or hyper-
thyroidism. Sometimes, though, it reflects a technical error
in applying the continuity equation, when the blood acceler-
ates within the LVOT due to an upper septal bulge, which
may result in an overestimation of valve area. To avoid
this, one can try to measure the LVOT area at the point of
maximal velocity, though the geometry is often quite dis-
torted in this region,making estimation of theLVOTarea dif-
ficult. Alternatively, one can use the LV stroke volume (from
2D or three-dimensional [3D] measurements of the LV, ide-
ally with contrast infusion) or right ventricular (RV) stroke
volume (fromRVoutflow tract) as the input into the continu-
ity equation. Dividing this stroke volume by the time veloc-
ity integral of the AV continuous-wave Doppler will also
yield the AVA, independent of any distortion in the LVOT.
Despite the convenience and wide-spread applicability of
transthoracic echocardiography (TTE), there are occasions
when invasive measurements are needed, such as in patients
with a discrepancy between clinical and echocardiographic
assessments. In such cases, catheterization should generally
be performed with dual catheters, 1 placed in the LV, the
other in the proximal aorta to obtain simultaneous pressure
measurements and obtain the most accurate assessment of
the gradient. Infusion of dobutamine may allow assessment
of low-output, low-gradient AS in the catheterization labo-
ratory.23 Other adjunctive testing used in quantifying AS in-
cludes transesophageal echocardiography (TEE),24 CT
scanning (dynamic or gated during systole),25 and CMR.26
2.2.2. Stress Testing
The presence or absence of symptoms should guide the
management of AS patients, yet in many cases, this impor-
tant clinical benchmark is difficult to establish, owing to the
subjective nature of the symptoms and comorbid conditions
such as chronic lung disease in this patient population. In
general, stress testing is contraindicated when symptoms
are present because of the potential for complications in
these patients. However, in patients with equivocal symp-
toms, stress testing, and in particular stress echocardiogra-
phy, can be very helpful.27 Simple determination of
functional capacity may help show limitations of which
a patient may be unaware. Isolated echocardiographic
(ECG) changes during the stress test without symptoms or
change in blood pressure should not be interpreted as a pos-
itive indicator of severe AS. Other potential markers for AS
severity include signs of LV dysfunction on exercise echo or
a rise in left atrial or right ventricular pressure.28,29e34 The Journal of Thoracic and Cardiovascular Surg2.3. Special Considerations
2.3.1. Symptom Status
With severe, symptomatic, calcific AS, AVR is the only
effective treatment that improves symptoms and prolongs
survival.30,31 These results are partly dependent on LV
function. In the setting of LV dysfunction caused by
afterload mismatch, survival is still improved, although
improvement in LV function and resolution of symptoms
might be incomplete after AVR. Age itself is a risk factor
for adverse outcome, but it is not a contraindication to
AVR even in the very elderly.32,33
2.3.2. Associated Coronary Artery Disease
In patients with moderate AS, who are undergoing coro-
nary artery bypass graft surgery (CABG), AVR should be
performed at the time of revascularization irrespective of
symptoms related to moderate AS.34,35 There are no data
to support performing AVR for mild AS at the time of
CABG. Patients undergoing surgical AVR with significant
stenoses (>50% to 70% stenosis) in major coronary
arteries should be treated with concomitant CABG.
Options in patients with combined AS and CAD continue
to grow with the use of hybrid procedures where PCI is
followed by valve surgery. It is possible that such
a strategy could be performed in the setting of TAVR.36,37
2.3.3. Associated Lesions—AR, MR, Pulmonary
Hypertension, TR
Patients with severe AS often have additional associated
significant valvular heart disease. Treatment of these lesions
in patients undergoing AVR should be undertaken using
standard criteria. However, treatment of associated valvular
lesions may increase the risk of AVR.38 A special circum-
stance is that of pulmonary hypertension (PH) either pri-
mary or secondary (reactive or related to increased LV
end-diastolic pressure). Both conditions may increase the
risk of AVR and must be taken into consideration in the
risk/benefit ratio.
PH can be present in patients with severe AS, either from
the transmission of increased LV diastolic and/or left atrial
pressures, associated mitral regurgitation (MR), or from
a secondary increase in pulmonary vascular tone. The prev-
alence of PH in patients with AS is undefined, varying
widely on the definition used and the population stud-
ied.39,40 Clinically, PH associated with critical AS
portends a poor prognosis and is associated with an
increased risk of sudden cardiac death.41 Consistent with
the surgical valve implant experience, PH after TAVR is
a predictive factor for both early (30-day) and late (1-
year) mortality, similar in risk to major access site compli-
cations and renal insufficiency.39,42-46 The presence of PH
makes patients more susceptible to any hemodynamic and
electrical instability related to the procedure and mayery c September 2012
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addition, PH may result in right heart failure and severe
tricuspid regurgitation (TR), both of which complicate
management and increase risks.
In the setting of severe AS and PH several treatment strat-
egies have been used.47 Persistently elevated left-sided car-
diac filling pressures increase the risk of pulmonary edema
when challenged with a pulmonary vasodilator. Pulmonary
vasodilators, such as nitric oxide, prostacylin, and sildena-
fil, have been administered during and following cardiac
surgery with improved hemodynamic effects.48-50
However, their overall clinical utility in improving late
survival in the surgical population and their role in TAVR
remains unclear. Further investigation is needed to
determine the optimal procedural and periprocedural
management of patients with AS and PH undergoing TAVR.2.3.4. Low Gradient–Low EF
As mentioned, the combination of overt congestive heart
failure and low aortic valve gradient is relatively common.
This may be a consequence of excessive afterload (despite
left ventricular hypertrophy [LVH]) or reduced contractile
function51 likely due to increased myocardial fibrosis.52
When there is overt heart failure due to low forward flow
and a low transvalvular gradient (mean gradient 30 mm
Hg), both mechanisms may be present. Because of reduced
contractility in the low-flow/low-gradient AS patient, prog-
nosis with surgical AVR is adversely affected with operative
mortality as high as 20%. However the 5-year survival is still
reported to be better in patients treated surgically.53,54 When
the primary reason for poor LV performance is excessive
afterload, the prognosis following surgical AVR is usually
good.14 In general, patients with low gradient, low EF who
have the best prognosis are those with inotropic reserve
(shown by an increase in stroke volume with dobutamine in-
fusion), who have limited coronary disease and a mean gra-
dient that although low, still exceeds 20 mm Hg.532.3.5. Basal Septal Hypertrophy—Outflow Tract
Gradients
Although infrequent, proximal septal bulging with LVOT
obstruction may present unique issues in the presence of
AS. While this can be readily addressed during AVR via
myomectomy, such an approach would not be possible
with TAVR. Thus, careful preprocedural echocardiographic
screening is recommended to specifically avoid this sce-
nario in patients being considered for TAVR.3. CURRENT TREATMENT OPTIONS
3.1. Surgical AVR
AVR is the only effective treatment considered a Class I
recommendation by ACCF/AHA and ESC guidelines inThe Journal of Thoracic and Caadults with severe symptomatic AS.28,29 Not only does it
offer symptomatic relief, the operation improves long-
term survival. Since 1960, when AVR was first introduced,
advancement in prosthetic technology including improved
hemodynamics, durability and thromboresistance, and tech-
niques in cardiac surgery such as cardioplegia, management
of the small aortic root, resection of associated subvalvular
disease, and replacement of associated aortic aneurysm
have resulted in improvements in both operative and long-
term results.
3.1.1. Valve Type
Current AVR options include mechanical, bioprosthetic,
and in specific situations homograft and autograft tech-
niques. Each has their advantages and drawbacks, but the
trend in some centers in the recent era has been toward tis-
sue valve replacement in a majority of patients because of
improved durability and the lack of requirement for antico-
agulation therapy.
3.1.1.1. Mechanical Valves
Mechanical valves are now extremely durable, have ex-
cellent hemodynamics, and are minimally thrombogenic
with adequate anticoagulation. Current anticoagulation is
mostly based on Vitamin K antagonists. Newer agents
such as oral direct thrombin inhibitors and factor Xa inhib-
itors have been studied in other patient populations, mainly
atrial fibrillation, and have been found to be associated with
decreased bleeding risk and minimum drug or food interac-
tion.55 They have not been well studied in patients with
AVR.With warfarin there is a risk of serious thromboembo-
lism of approximately 0.5% a year and a similar risk of ma-
jor hemorrhage annually.56 Mechanical valves are typically
preferred in younger patients given their reliable long-term
durability.
3.1.1.2. Bioprosthetic Valves
Compared with mechanical valves, bioprosthetic valves
do not require anticoagulation with warfarin, and thus
have a lower risk of bleeding. However, long-term durabil-
ity varies substantially with age for these valves. Structural
valve degeneration leading to symptoms or reoperation,
commonly associated with calcification of the biologic leaf-
lets, occurs at an average of 10 to 12 years in younger pa-
tients and 15 to 18 years in older patients. Actuarial
freedom from reoperation following implant of a modern
bioprosthetic valves is approximately 95% at 5 years,
90% at 10 years, but drops to 70% at 15 years.57 Thus, bio-
prosthetic valves are generally preferred in older patients
who are unlikely to tolerate bleeding risk associated with
anticoagulation treatment and in whom a 15-year durability
is reasonable. In patients with bioprosthetic valves, if pros-
thetic dysfunction occurs, TAVR may play an important
role in solving the clinical issues in the future.rdiovascular Surgery c Volume 144, Number 3 e35
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Current data from the Society of Thoracic Surgeons
(STS) registry documents a mortality that is under 3% for
all patients undergoing AVR. As with any procedure, oper-
ative mortality is strongly correlated with the severity of the
disease and comorbidity of patients. The operative risks can
be estimated with online risk calculators from the STS
(http://209.220.160.181/STSWebRiskCalc261/) and the
European System for Cardiac Operative Risk Evaluation
(www.euroscore.org).58,59 In selected patients with
minimal comorbidity, mortality and major morbidity are
under 1% each in many centers. In general, perioperative
stroke rates are 1.5% (with major life-debilitating stroke
being somewhat less) and other major complications are
relatively rare. Renal failure, pulmonary failure, and gastro-
intestinal complications are not common. As older, more
frail patients with extensive comorbidities undergo AVR,
the risk of death and morbidity as well as length of
hospitalization increases significantly.60,61 In addition to
comorbidity, preoperative functional performance is also
a maker of postoperative morbidity/mortality.
A recent study reviewed the results of high-risk surgical
AVR in 4 centers with significant experience. The patients
were a mean age of 76 and the mean STS predicted risk
of mortality was 16.3%. Complications included stroke in
4.4%, new permanent pacemaker in 5%, multisystem or-
gan failure in 6.9%, pneumonia in 7.5%, and dialysis in
8.2%. Postoperative length of stay was 12.6 days and in-
hospital mortality was 16.4%. One-, 3- and 5-year survival
was 70.9%, 56.8%, and 47.4%. This study was performed
between 2002 and 2007 in 4 centers before participation in
the PARTNER Trial commenced and therefore serves as
a reasonable baseline for comparing the results of TAVR.62
3.1.3. Patient Selection
Patient selection for AVR for AS is well outlined by
ACCF/AHA and ESC guidelines.29,63 Problems arise
when the clinicians and patients note significant
symptoms and significant structural disease that are
complicated by the presence of significant comorbidity.
Although current STS risk score and EuroSCORE give
information concerning short-term operative risks and ben-
efits, they are not able to predict symptom resolution,
quality-of-life improvement, or return to independent
living.
3.1.3.1. Use of STS and euroscore Models in Patient Selec-
tion for Conventional AVR
Although a number of risk algorithms for cardiac surgery
have been developed, the STS and logistic EuroSCORE are
the most commonly used. Although both are accurate in
low-risk patients, accuracy is less in higher-risk subsets.
These 2 scores include different covariates. The logistic
EuroSCORE is based on 12 covariates derived frome36 The Journal of Thoracic and Cardiovascular Surg14,799 patients undergoing all types of cardiac operations
(mostly coronary bypass) in 8 European countries in 1995.
On the other hand, the STS risk predictor is based on 24 co-
variates derived from 67,292 patients undergoing isolated
AVR only in the United States over a relatively more con-
temporary period between 2002 and 2006. The STS model
is the standard most commonly used in the United States.
3.1.3.2. Patient Risk of AVR
Information from the STS National Database shows
that the operative mortality for isolated AVR has declined
from 3.4% in 2002 to 2.6% today (http://www.sts.
org/sites/default/files/documents/20112ndHarvestExecutive
Summary.pdf). The most important preoperative patient
risk factors are the need for emergency surgery, the pres-
ence of endocarditis, and a history of previous cardiac sur-
gery. The present models do not include some risk factors
that may be particularly important in the prediction of out-
comes for very high-risk populations including frailty, PH,
porcelain aorta, and the presence of hepatic dysfunction,
although all have been added to a recent upgraded
version.64,65
It should be emphasized that risk models serve as 1 aspect
of patient selection, but need to be considered in concert
with clinical judgment and the other methods of risk assess-
ment. In the final analysis, patient risk and benefit is deter-
mined, not by statistical models, but by the experience,
knowledge, and expertise of the physicians charged with
rendering care.
3.1.3.2.1. Specific Surgical Risks
3.1.3.2.1.1. Stroke. Although ischemic stroke can result
from many causes after AVR, a major concern is the role
of thromboembolism. The risks of thromboembolism are
usually greater in the first few days and months after bio-
prosthetic AVR implantation before the sewing ring of the
prosthesis is endothelialized66; risks after mechanical
AVR continue. The risk of stroke within 30 days among
67,292 cases of AVR in the STS Registry was 1.5%; this
data set was used to develop a model for predicting
30-day stroke risk.61 Within the STS database among
108,687 AVR operations between 1996 through 2006, the
risk of in-hospital permanent stroke decreased 21% from
1.7% to 1.3%.67 It is important to note, however, that inde-
pendent neurological assessment was not done in these pa-
tients, so the actual stroke incidence in these patients may
be underestimated. Overall, embolic stroke risks are greater
with mechanical valves, which require long-term oral anti-
coagulation, than with bioprosthetic valves, which have
a 0.7% per year risk of thromboembolism in patients with
normal sinus rhythm without warfarin anticoagulation.68
Of note, many AVR patients are older, with other comor-
bid cardiac conditions that increase stroke risk, includingery c September 2012
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aortic arch atheroma.69 However, even carefully selected
octogenarians can safely undergo AVRwith a 2% incidence
of stroke.32,70
Because of the risk of stroke, the 2006 ACC/AHA guide-
lines for the management of patients with valvular heart dis-
ease include a variety of recommendations regarding the
use of antithrombotic therapy to reduce thromboembolism
risk after AVR.63 The choice of antithrombotic agents in-
clude warfarin with target international normalized ratios
(INRs) typically in the range from 2.0 to 4.0 depending
on the specific prosthesis, aspirin 75 mg to 325 mg per
day, and clopidogrel 75 mg per day, as well as combina-
tions. Recommendations depend upon the type of valve,
timing after surgery, presence or absence of risk factors
such as atrial fibrillation, and ability of the patient to take
warfarin or aspirin.63
Given the greater risk of thromboembolism, particularly
stroke, which usually occurs within the first 72 hours post-
procedure, many centers start heparin (target aPTT 55 s to
70 s) as soon as the risk of surgical postoperative bleeding
is acceptable, which is usually within 48 hours of surgery.
Heparin can be discontinued when warfarin therapy reaches
a therapeutic INR usually above 2.0.63
3.1.3.2.1.2. Other Complications. Aside from other surgi-
cal complications of renal, hepatic, neurological, and pul-
monary disease compromise, a major risk of conventional
AVR is sternal wound infection. In most centers, this risk
is under 1% for deep infection, but the risk of any type of
infection is still present and particularly increased in pa-
tients with diabetes, obesity, smoking, immunosuppressive
therapy, and prior radiation therapy. With the advent of neg-
ative pressure wound therapy and continued advances in
surgical technique, these risks are now rarely fatal, but re-
main morbid. Blood requirement after valve replacement
can lead to hepatitis C, human immunodeficiency virus,
or other viral infection. These transfusion-acquired infec-
tions are now extremely rare due to transfusion guidelines
and systems precautions.
3.1.3.3. Prohibitive Risk, Extreme Risk, Inoperability
Despite substantial contemporary experience with suc-
cessful AVR in elderly patients, multiple series have docu-
mented that 30% to 40% of patients with severe AS do not
undergo surgery owing to advanced age, LV dysfunction,
multiple coexisting conditions, and patient preference or
physician recommendation.71-76
The definitions used to describe patient populations con-
sidered for TAVR vary; for example, prohibitive risk would
describe a patient in whom the procedure could be per-
formed from a technical standpoint but would be associated
with prohibitively high morbidity and mortality.77 Inoper-
ability might identify a patient group in whom technicalThe Journal of Thoracic and Casuccess would not be possible; for example, no vascular ac-
cess. Different trials have used these terms for patient en-
rollment; for example, the CoreValve Trial identifies
extreme risk, whereas the PARTNER (Placement of AoRtic
TraNscathetER Valve) Trial used the term inoperable. For
this document, we prefer the term prohibitive risk. This in-
cludes some patients in whom surgery might be deemed un-
suitable based on the physician’s assessment of the patient’s
risk for surgery; whereas in others, the surgeon may decide
that the operation cannot be performed successfully be-
cause of technical considerations. Assessment of inoper-
ability is also driven by surgeon and institutional
experience and thus varies. The incidence of patients under-
going AVR with an STS predicted risk of mortality>5% is
low but vary significantly amongst institutions and may be
related to volume and referral patterns. Experience with
such patients is pivotal for TAVR teams. Referral to such
team and another opinion/consultation is crucial before
deeming a patient inoperable. Whereas practice guidelines
have been developed to assist physicians and surgeons in
determining appropriate use of treatment options,29,63
there are, however, no specific recommendations for
defining inoperability. Current ACCF/AHA guidelines
acknowledge that special considerations are required for
the management of advanced elderly patients with AS,
since age-related and comorbid conditions commonly exist
in patients in their 80s and 90s even though AVR is techni-
cally feasible even in this group.67,78
In the absence of literature evidence andguidelines recom-
mendations, the determination of inoperability in any given
patient depends on the judgment of the medical team. It is
generally agreed that patients with limited life expectancy
due to concurrent conditions such as malignancy, dementia,
primary liver disease, chronic obstructive pulmonary disease
(COPD), among others, are not appropriate for AVR. Frailty
and related conditions of debility and deconditioning are
known to result in inability to recover from major heart sur-
gery such asAVR,despite operative survival andhospital dis-
charge.65 These conditions can potentially contribute to
increased surgical mortality and morbidity in the elderly.79
Inoperability from the surgeon’s judgment may result
from technical considerations that preclude safe perfor-
mance of AVR, such as prior mediastinal irradiation, porce-
lain aorta or severe periannular calcification, severe aortic
atheromatous disease, prior cardiac operations, among
others including the internal mammary artery crossing the
midline. Although infrequent, aortic valve bypass with
a LV apex-to-descending aortic conduit has been used in
some patients with severe AS judged to be inoperable via
a mediastinal approach and cardiopulmonary bypass.80
In summary, a substantial percentage of patients with AS
are judged to be inoperable for surgery based primarily on
the physician’s or surgeon’s determination of operative
risk and survivability. Although some patients may be foundrdiovascular Surgery c Volume 144, Number 3 e37
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operable patients are felt to be too ill from associated co-
morbid conditions.
3.2. Alternatives to AVR
3.2.1. Medical Therapy
There are no proven medical treatments to prevent or de-
lay the disease process in the aortic valve leaflets. However,
evaluation and modification of cardiac risk factors is impor-
tant in patients with aortic valve disease to prevent concur-
rent coronary artery disease (CAD). The association of AS
with risk factors similar to those associated with atheroscle-
rosis5,6 had suggested that intervention may be possible to
slow or prevent disease progression in the valve
leaflet,81,82 but prospective, randomized, placebo-
controlled trials failed to demonstrate a benefit of statins
in reducing the progression of aortic valve stenosis.
Longer-term palliative medical management of symp-
tomatic AS may be appropriate for patients who are either
not candidates for aortic valve surgery due to comorbidities
or in patients who refuse AVR. The overall goal of medical
therapy is to treat coexisting cardiovascular conditions, and
treat superimposed diseases that often exacerbate the dis-
ease process. Patients should be educated about the effects
of sodium intake, change in weight, and other factors that
may lead to clinical decompensation. Medical therapy
should be judicious and include treating concurrent cardio-
vascular conditions such as correction of anemia and fever,
and preventative measures such as pneumococcal or influ-
enza vaccination. Given the severe hypertrophy, optimizing
hemodynamics by maintaining sinus rhythm may help with
symptom stabilization.
Even with optimal care, adults with severe symptomatic
inoperable AS will have exacerbations of symptoms and
frequent hospitalizations. Palliative care should include
end-of-life discussions and counseling as appropriate.
Counseling is also indicated regarding true risk of AVR,
and the importance of accurate risk prediction cannot be
overemphasized. Many patients may refuse surgery based
on misunderstood operative risk.
3.2.2. Balloon Aortic Valvuloplasty
First reported in 1986,83 balloon aortic valvuloplasty was
considered to be a less invasive and safe alternative to AVR,
particularly in high surgical risk patients with multiple med-
ical comorbidities. Although balloon aortic valvuloplasty
results in immediate hemodynamic improvement with a sig-
nificant decrease in transvalvular gradients resulting in
larger valve area, it does not result in sustained clinical im-
provement because of high recurrence rates; restenosis or
recoil of the aortic valve usually occurs within 6 months.
Patients treated with balloon aortic valvuloplasty alone
have shown poor prognosis, with survival rates of 50% ate38 The Journal of Thoracic and Cardiovascular Surg1 year, 35% at 2 years, and 20% at 3 years.15,84-86
In addition, serious complications due to balloon aortic
valvuloplasty occur in 15% to 25% of patients.84,87,88
Balloon aortic valvuloplasty, therefore, should not be used
as a substitute for AVR in patients who are candidates for
surgical AVR. Even as a palliative treatment, balloon
aortic valvuloplasty data suggest that there is much
uncertainty regarding improved longevity or quality of
life after the procedure with a mean duration of symptom
improvement of only 1 year.63,89 There has been no
significant difference in long-term survival demonstrated
between patients undergoing balloon aortic valvuloplasty
and those undergoing medical therapy alone.86 Although
balloon aortic valvuloplasty as a stand-alone treatment is
not recommended,63,87,88 it may still be used in
contemporary practice as a bridge to subsequent AVR (both
Class IIb, Level of Evidence C recommendation).28,84,90 In
the current era of TAVR, there has been increased interest
in balloon aortic valvuloplasty. In this setting, balloon
aortic valvuloplasty may be used to assess whether there is
initial clinical improvement, in which case, then the patient
may be a candidate for TAVR.
4. TRANSCATHETER AORTIC VALVE
REPLACEMENT
4.1. Background and History
Given the increased mortality and morbidity of AVR
surgery for high-risk patients and the poor long-term re-
sults of balloon aortic valvuloplasty, there has been interest
in the development of a percutaneously delivered aortic
heart valve.91 As early as 1992, investigators evaluated
stent-based porcine bioprostheses delivered to various aor-
tic sites in animal models.92 This early work culminated in
2000 with implantation of a percutaneous heart valve in
a 12-year-old patient with a failing right ventricular to pul-
monary arterial conduit that had been placed 8 years pre-
viously for the treatment of pulmonary atresia and
ventricular septal defect. This initial seminal experience
was followed in 2002 by the first human TAVR using the
antegrade approach to implant a balloon expandable
equine pericardial leaflet stent valve.93 Since that early ex-
perience, there have been multiple iterations and a number
of new designs.
4.2. Device Description
At the present time, the most data available for TAVR are
based upon 2 specific devices—the Sapien valve (Figure 1)
Edwards Life Sciences, Inc, Irvine, Calif) and the Core-
Valve (Figure 2) (Medtronic, Inc, Minneapolis, Minn).
The most recent iteration of the former is a trileaflet bovine
pericardial valve mounted with a tubular slotted balloon-
expandable stent composed of a cobalt chromium alloy.
The Sapien valve is available in 23-mm and 26-mm sizesery c September 2012
FIGURE 2. CoreValve. The Medtronic CoreValve System is currently
limited to investigational use in the United States. Source: Medtronic, Inc.
FIGURE 1. Sapien valve. Source: Edwards Lifesciences.
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in Europe. The initial devices required a 22- or 24-French
sheath for delivery of the prosthesis. Recent iterations (No-
vaFlex) have decreased this to 18-French. The first and sec-
ond generations of this device have been tested in
randomized controlled trials for both transfemoral and
transapical implantation.
The second device (CoreValve) is comprised of 3 porcine
pericardial tissue leaflets mounted in a self-expanding niti-
nol frame. It is available in 3 sizes—26 mm, 29 mm, and 31
mm. This valve has also continued to iterate, with the initial
devices being 25-French, but now 18-French delivery
sheaths are used. This valve has only been used by a retro-
grade approach—either via transfemoral, subclavian, or di-
rect aortic access.
A wide range of new devices has been tested with some
first-in-man experiences. These devices have been charac-
terized by smaller size, the ability to reposition or even re-
capture the device after deployment if an optimized device
position is not obtained initially, and, modular prosthetic el-
ements to design in situ more optimal conformance to the
natural valve and aortic annulus among others.
Specific anatomic issues must be considered in device
design. These include the rigid structure of the pattern of
valvular calcification and aortic annulus, and the need for
as full apposition as possible to the annulus in an attempt
to minimize periprosthetic leak which, given sometimes
eccentric, bulky calcification, may be difficult. The close
proximity to the coronary ostia, the width and height of
the sinuses, the membranous ventricular septum with theThe Journal of Thoracic and CaHis bundle and the anterior leaflet of the mitral valve are
also important anatomical considerations. In addition, the
size and degree of severity of peripheral arterial disease
are all factors that could limit catheter size. Other issues in-
clude avoidance of central prosthetic leak, leaflet durability,
hemodynamic performance, ability to treat both tricuspid
and bicuspid valve anatomy, surfaces designed to minimize
thrombogenicity, and the need to optimally position the
devices and retrieve and reposition when necessary.94
Fundamental issues for all current and future devices are
hemodynamic results, valve durability, and residual or new
aortic regurgitation (AR). The initial hemodynamic perfor-
mance of TAVRvalvesmust be similar or superior to that ob-
tained with surgical AVR. This is crucial because high
residual transprosthetic gradients result in less symptomatic
improvement and poorer regression of left ventricular
mass.95 These transprosthetic gradients are a function of
prosthetic size as well as the specific type of prosthesis
and can result in patient–prosthesis mismatch. Typical im-
mediate postprocedural gradients after surgical AVR range
from8mmHg to 12mmHg,whereas theAVarea or effective
orifice area (EOA) ranges from 1.4 to 1.9 cm2. As docu-
mented below in the PARTNER trial, the valve hemodynam-
ics of the TAVR early on are approximately 10% better than
the specific surgical aortic prostheses used in that trial.
There are only limited clinical data on the durability of
TAVR valves—up to 2 years—in the PARTNER trial and
up to 5 years in other registry experiences. Although the ab-
solute number of patients is small, there have been no reports
of structural valve deterioration. The fundamental clinical
need for durabilitymay depend in part on the specific patientrdiovascular Surgery c Volume 144, Number 3 e39















Age (y) 83 82 83 83 83
Female (%) 55 56 49 46 44
EuroSCORE (mean,%) 26 24 23 29 26
NYHA functional class III/IV (%) 89 76 75 80 93
Aortic valve area (cm2) 0.59 0.70 0.67 0.60 0.63
Mean gradient (mm Hg) 45 49 48 47 48
Prior CABG (%) 26 15 19 20 30
Ejection fraction (%) 51 52 53 50 55
Outcomes
30-day mortality (%) 10.4 7.5 7.8 8 9.5
1-y mortality (%) 24 18.9 NR NR NR
Stroke (%) 3.3 3.5 3.5 5.0 3.0
Major vascular complications (%) 27.9 11.3 11.3 NR 13.1
Permanent pacemaker (%) 1.8 6.7 8.5 4.0 3.6
Data are derived from the Edwards Lifesciences briefing document for the U.S. Food and Drug Administration (FDA) Circulatory Devices Advisory Panel meeting on TAVR on
July 21, 2011 (http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/
ucm240575.htm). CABG, Coronary artery bypass graft; NR, not reported; NYHA, New York Heart Association; TF, transfemoral.
Clinical Guidelines Holmes et alpopulation. In the PARTNER trial, the mean age at implant
was 83 years, and serious comorbidities were frequent. In
this setting, the need for durability of 20 years is less impor-
tant than if the patient selection criteria are broadened to in-
clude patients in their early to mid 60s who have isolated AS
without comorbid conditions. In this latter group, the TAVR
valve must have at least equivalent clinical durability to cur-
rently available surgically implanted valves.
4.3. Current State of the Evidence
4.3.1. Registry Experience
Registry data provide important information for assess-
ing the role of TAVR in a large number of patients who









Age (y) 82 79 82.5
Female (%) 56 47 51.5
EuroSCORE (mean,%) 23 26.6 24.7
NYHA functional class III/IV (%) 71.5 69 74.6
Mean gradient (mm Hg) 52 54 46
Outcom
Procedural success (%) 98 98.4 92.6
30-day mortality (%) 5.9 2.2 15.1
1-y mortality (%) 15 18.4* NR
Stroke (%) 2.5 2.2 4.5
Major vascular complications (%) 2.0 21.3 7.5
Permanent pacemaker (%) 19.1 26.1 25.7
N, Number; NR, not reported; NYHA, New York Heart Association. *6-month survival, **
e40 The Journal of Thoracic and Cardiovascular Surgof strict selection criteria. Several multicenter registries, in-
cluding Edwards Lifesciences and Medtronic CoreValve
(Tables 1 and 2), have reported early and late outcomes
with TAVR. However, patient selection criteria varied
amongst the different registries; standardized definitions
for clinical events such as those described by the Valve
Academic Research Consortium (VARC)96 were not used;
and endpoints were not prospectively adjudicated using
a blinded clinical event committee.
CoreValve system real-world clinical experience to date
is comprised of multiple registries from several participat-
ing national sites.97,105-110,115 These study sizes range
from 61 to 663 patients, with a combined clinical patient
experience of nearly 2350 patients that includes follow-up











78.6 81 81.3 81.4 81.9
54.6 NR 48 55.8 57.1
16 22 18.1 20.8 23.4
58.4 74 73.9 88.2 74.6
55 NR NR 48.7 46.8
es
98.1 97.5 98.2 NR 72.6
7.4 4.7 5.8 12.4 15.2
17.7 NR 21.7 NR 38.1**
0.0 4.2 4.0 2.8 NR
5.6 9.0 6.2 4.0 NR
35.2 26 24.4 42.5 26.2
2-year survival.
ery c September 2012
Holmes et al Clinical Guidelines4.3.1.1. Demographics
Tables 1 and 2 summarize the major patient
characteristics for the Sapien and CoreValve family of
registries, respectively. The patients selected for entry are
elderly (average age typically over 80 years), with
symptomatic severe AS (mean gradient 45 mm Hg),
significant comorbidities, and an average EuroSCORE of
23 (Sapien) and >16 (CoreValve),97,105-110 indicating
a significant risk with conventional AVR. However, unlike
the PARTNER trial, all of these registries used the
EuroSCORE risk prediction system for defining high risk
and inoperability. EuroSCORE is generally not regarded
as valid in high-risk patients for surgical AVR, and surgeon
input as to operabilitywas not required in these registries. As
a result, the registry results are difficult to interpret because it
is unclear whether the patients who were enrolled in these
registrieswere truly ‘‘inoperable’’versus ‘‘high-risk.’’110,111
4.3.1.2. Outcomes
4.3.1.2.1. Procedural Success and Hazards. In the
SOURCE (SAPIEN Aortic Biosprosthesis European Out-
come) registry, procedural success rate (defined as 1 valve
implanted, AR<2þ, and patient left procedure room alive)
was 93% for transfemoral TAVR and 92% for transapical
TAVR. The procedural success rate reported for CoreValve
is>92% except for 1 study that enrolled very high-risk pa-
tients.105 Significant variations between registries were not
observed in terms of deployment, relief of obstruction and
avoidance of significant AR.110,111
4.3.1.2.2. Early and Late Morbidity and Mortality. The
early and late major outcomes with Sapien and CoreValve
registries are summarized in Tables 1 and 2. The early
morbidity of TAVR includes strokes, coronary occlusion,
pacemaker implantation, vascular complications, renal
failure, cardiac rupture and tamponade, bleeding, aortic
dissection, and death. The overall risk of any 30-day major
complication ranges from 20% to over 40%. Early mortal-
ity ranges from an in-hospital rate of 5% to 8% and
a 30-day mortality rate from 8% to 10%. In the SOURCE
registry, the incidence of a major bleeding event was signif-
icantly greater among patients undergoing transapical
versus transfemoral TAVR (3.9% vs 2.3%), whereas the
incidence of vascular access-related complications was sig-
nificantly higher among patients having transfemoral TAVR
(major—11.3% vs 2.0%; minor—10.4% vs 1.0%).110-114
Permanent pacemaker placement is reported in between
1.8% up to 8.5% of patients with Sapien and 19.1% to
42.5% with the CoreValve; renal failure in under 3%; and
stroke in 1% to 5%. Registry data reflect an overallmortality
rate at 1 year of 19% to 24%. In the SOURCE registry, more
than half (51.6%) of deaths up to 1 year had a noncardiac eti-
ology and were related to baseline comorbidities.110,111The Journal of Thoracic and CaThe recent UK TAVR Registry included 452 Medtronic
CoreValve implantations.115 In this group, standardized
data forms were used and audited. Procedural success was
achieved in 98.2% in this high-risk group of patients who
had a baseline logistic EuroSCORE of 18.1%. Thirty-day
mortality was 5.8%, and 1- and 2-year mortality was
21.7% and 23.9%, respectively. In-hospital stroke occurred
in 4% of patients and myocardial infarction in 1.1%. A per-
manent pacemaker was required in 24.4% (compared with
7.4%with Sapien). Rates of moderate to severe postimplant
AR were 17.3% (compared with 9.6% with Sapien). Mor-
tality rates at all time points were significantly lower among
patients treated via a transfemoral route as compared with
nontransfemoral routes (>85% transapical). In this study,
LV function, the presence of moderate/severe AR, and
COPD, but not vascular access site, were independent pre-
dictors of mortality.
4.3.1.2.3. Quality of Life in Registries. Quality of life is
a key patient-centered outcome. Although death is the low-
est possible functional status, for many, survival marked by
reduced physical function or independence may be worse
than death. The PARTNER EU Registry is a multicenter
study of the early European experience in TAVR. Patients
undergoing TAVR by transapical or transfemoral approach
were followed to 12 months for symptoms by New York
Heart Association (NYHA) functional class, and heart fail-
ure–related quality of life as assessed by the Kansas City
Cardiomyopathy Questionnaire.116 All patients improved,
with no significant differences in NYHA functional class
improvement noted between transapical or transfemoral
approaches.
Several single-center registries have added additional
information on quality of life using disease-specific or
general surveys (Short Form-36 Health Questionnaire,
Short Form-12 Health Questionnaire, Kansas City Cardio-
myopathy Questionnaire, Minnesota Living with Heart
Failure Questionnaire) and on symptoms (NYHA func-
tional class, and 6-minute walk). Improvements following
TAVR in vitality, physical functioning, and general and
mental health scores have been identified with physical
function demonstrating the greatest improvement. Patients
who do not experience improvement are more likely to
have comorbidities that contribute to continued symptoms
and impair quality of life, such as COPD and reduced EF
(Table 3).
4.3.1.2.4. Learning Curve. Each registry has identified
a procedural learning curve, but the exact definition of
this curve and a clear method to decrease it are not yet
clearly reported. This curve has important components
such as patient selection, anesthesia, improvement in the
equipment over time, and technical decision making regard-
ing valve deployment. The SOURCE registry enrolled 1038rdiovascular Surgery c Volume 144, Number 3 e41
TABLE 3. Quality of life and symptom assessment in TAVR registries
Study population NYHA functional class 6-Minute walk Questionnaire Other
PARTNER EU Registry;
Lefevre et al (multicenter;
N ¼ 130 Sapien)116
Improved class at 1 year in
84.5% of patients (85%
NYHA functional class III/
IVat baseline, 15% NYHA
functional class at 1 year);
changes noted at 30 days
were sustained
NR KCCQ improvement at 1 year
in 72.7% (P<.0002)
Small improvement in EQ-5D
was not significant
Buellesfeld et al
(multicenter; N ¼ 126
CoreValve)105
Improved in 80% at 30 days;
74% at 2 years (in 50% by
1 level, in 20% by 2 or
more levels)
NR NR NR
Krane et al (single-center
registry; N ¼ 99 TAVR)117
More class I/II at 3 months
(NYHA functional class
III/IV from 98% to 2% at 3
months)
NR Improved SF-36 PF general
health and vitality pre/post
at 3 months (all P<.01).
No change mental health.
85% would do TAVR again
Ussia et al (single-center
registry; N ¼ 57 TAVR)118
More class I/II (average 1.8
NYHA functional class
improvement) at 5 months
(P<.001)
NR SF-12; Improved (P<.001)
physical and mental




Bekeredjian et al (single-
center registry; N ¼ 87
TAVR)119
Improved class (average of
1.7 NYHA functional class
improvement) at 6 months
(P<.001)
NR SF-36 Improved physical and
mental component scores,
greatest change in PF
70% average decrease in
NT-proBNP levels of 4000
ng/L (P<.0001)
Gotzmann et al (single-center
registry; N ¼ 44 TAVR)120
Decrease of percentage of
NYHA functional class III/






Lower average decrease in
BNP levels of 400 pg/mL
(P<.005) and 25%
increase in 6-minute walk
time (P<.005)
BNP, Brain natriuretic peptide; EQ-5D, EuroQol Five Dimensions; HF, heart failure; KCCQ, Kansas City Cardiomyopathy Questionnaire; LOS, length of stay; MLHFQ, Min-
nesota Living with Heart Failure Questionnaire; NR, not reported; NYHA, New York Heart Association; PF, physical function; QOL, quality of life; SAVR, surgical aortic valve
replacement; SF-12, Short Form 12 Health Questionnaire; SF-36, Short Form 36 Health Questionnaire; TAVR, transcatheter aortic valve replacement.
Clinical Guidelines Holmes et al(Cohort 1) and 1306 patients (Cohort 2) undergoing TAVR
procedures over 2 sequential years. Age and EuroSCORE
were not significantly different between the 2 cohorts. Com-
pared with the first year of experience, valve malposition
(1.6% vs 1.2%), and vascular access complications
(2.1% vs 1.8%) were not significantly lower in the second
year. However, reductions in the rates of postprocedure
AR >2þ (4.5% vs 2.1%, P ¼ .011) and conversion to
open surgery (3.7% vs 1.5%, P ¼ .0315) were im-
proved.110,111,121 Overall 30-day and 1-year survival was
similar in both cohorts despite higher number of patients
with heart failure and mitral regurgitation enrolled in
Cohort 2.
In summary, the registries demonstrate in high-risk pa-
tients that TAVR may be deployed with a high degree of
procedural success, predictable risk of stroke, device-
dependent high risk of pacemaker implantation (particu-
larly with CoreValve), and a 30-day mortality rate that
seems potentially acceptable in a debilitated and ill patient
population. Importantly, TAVR seems to alleviate AS to
a similar degree as surgical AVR and patients tend to returne42 The Journal of Thoracic and Cardiovascular Surgto Class I or II symptoms with substantial improvements in
quality of life.
Future registries should be designed to include contem-
porary (ie, VARC) definitions of procedural and quality-
of-life outcomes and utilize an independent clinical events
committee when possible to standardize event reporting.
Longer-term follow-up studies are needed to demonstrate
the continued durability of TAVR in the high-risk and inop-
erable patients.
4.3.2. Randomized Controlled Trial
4.3.2.1. PARTNER Trial Design
The PARTNER trial (Figure 3) was a prospective, un-
blinded, randomized, controlled, multicenter pivotal trial
evaluating the safety and effectiveness of the Edwards Sa-
pien THV transcatheter aortic valve; 2 distinct populations
were enrolled—inoperable, or Cohort B, and high-risk op-
erable, or Cohort A. Potential candidates were presented
on a national conference call for approval for treatment.
Randomization was stratified based on operability forery c September 2012
FIGURE 3. PARTNER trial design.
Holmes et al Clinical GuidelinesAVR surgery and within cohorts by vascular access for
transfemoral delivery. Patients who were considered high
surgical risk and eligible for transfemoral access were strat-
ified into Cohort A and randomized to treatment (transfe-
moral AVR) or control (surgical AVR). Cohort A patients
who were not eligible for transfemoral access were evalu-
ated as candidates for transapical delivery and, if appropri-
ate, randomized to treatment (transapical AVR) or control
(surgical AVR). Nonsurgical candidates were stratified
into Cohort B and randomized to treatment (transfemoral
AVR) or control (‘‘standard’’ therapy). Inoperability was
formally defined as ‘‘>50% predicted probability of mor-
tality or serious irreversible complication by 30 days by 1
cardiologist and 2 cardiothoracic surgeons.’’15 Cohort B pa-
tients who did not meet the criteria for transfemoral delivery
were not enrolled in the study because transapical delivery
was deemed too risky in Cohort B (Figure 3). Of the 3105
patients screened, a total of 1057 subjects (34%) were en-
rolled at 25 sites in 2 arms—699 patients in Cohort A and
358 patients in Cohort B. There were 2 co-primary end-
points for the inoperable cohort: (1) freedom from death
over the duration of the trial with all patients followed for
at least 1 year from randomization; and (2) hierarchical
composite of death and recurrent hospitalization. In the
high-risk cohort, the primary endpoint was freedom from
all-cause death at 1 year. Prespecified secondary endpoints
included rate of death from cardiovascular causes, NYHAThe Journal of Thoracic and Cafunctional class, the rate of repeat hospitalization due to
valve-related or procedural-related clinical deterioration,
the distance covered during a 6-minute walk test, valve per-
formance (assessed by echocardiography), and the rates of
myocardial infarction, stroke, acute kidney injury, vascular
complications, and bleeding. All patients were followed
during the index hospitalization; at 30 days, 6 months,
and 1 year; and yearly thereafter.
4.3.2.2. Demographics and Other Baseline Characteristics
The mean age was about 83 years in Cohort B and 84 in
Cohort A; slightly more patients were female (53.6%) in
Cohort B, and slightly more patients were male (57.2%)
in Cohort A; and most were Caucasian (Table 4). Over
92% in both cohorts were NYHA functional class III or
IV, and 60% of patients in both cohorts had undergone prior
CABG or PCI. Overall, the groups were balanced in most
baseline characteristics in Cohort A; however, there were
some imbalances in Cohort B.15 Patients in both cohorts
had relatively preserved LV systolic function.
Patients in Cohort B had greater frequency of coexisting
conditions that contributed to the surgeons’ determination
of inoperability, including an extensively calcified (porce-
lain) aorta (15.1%), chest-wall deformity or prior chest-
wall irradiation (13.1%), oxygen-dependent respiratory
insufficiency (23.5%), and frailty, according to prespecified
criteria (23.1%).rdiovascular Surgery c Volume 144, Number 3 e43
TABLE 4. Demographic and other baseline characteristics of the PARTNER trial (Cohort B data first)
Characteristic
Cohort B Cohort A
TAVR (N ¼ 179) Standard Rx (N ¼ 179) P value TAVR (N ¼ 348) AVR (N ¼ 351) P value
Demographics
Age (y) 83.1  8.6 83.2  8.3 .95 83.6  6.8 84.5  6.4 .07
Male (%) 45.8 46.9 .92 57.8 56.7 .82
STS score 11.2  5.8 11.9  4.8 .21 11.8  3.3 11.7  3.5 .61
Logistic EuroSCORE 26.4  17.2 30.4  19.1 .04 29.3  16.5 29.2  15.6 .93
NYHA functional class III or IV (%) 92.2 93.9 .68 94.3 94.0 .79
O2-dependent COPD (%) 21.2 25.7 .38 9.2 7.1 .34
Frailty (%) 18.1 28 .09 15.6 17.6 .58
Porcelain aorta (%) 19 11.2 .05 0.6 1.1 .69
Chest wall radiation (%) 8.9 8.4 1.00 0.9 0.9 1.00
Chest wall deformity (%) 8.4 5.0 .29 0 0.3 1.00
Echocardiographic characteristics
AVarea (cm2) 0.6  0.2 0.6  0.2 .97 0.7  0.2 0.6  0.2 .13
Mean AV gradient (mm Hg) 44.5  15.7 43.0  15.3 .39 42.7  14.6 43.5  14.3 .45
Mean LV EF (%) 53.9  13.1 51.1  14.3 .06 52.5  13.5 53.3  12.8 .45
Cohort B includes only nonsurgical candidates in whom ‘‘inoperability’’ was formally defined as greater than 50% predicted probability of mortality or serious irreversible com-
plication by 30 days by 1 cardiologist and 2 cardiothoracic surgeons. Cohort A includes patients determined to be at high operative risk defined as predicted operative mortality of
15% and/or an STS risk score of10%. The STS risk algorithm is based on the presence of coexisting illnesses in order to predict 30-day operative mortality. Data are derived
from the Edwards Lifesciences’ briefing document for the U.S. FDA Circulatory Devices Advisory Panel meeting on TAVR on July 21, 2011 (http://www.accessdata.fda.gov/
cdrh_docs/pdf10/P100041b.pdf) and may show some discrepancies compared with the published manuscripts. AV, Aortic valve; AVR, aortic valve replacement; LVEF, left ven-
tricular ejection fraction; NYHA, New York Heart Association; Rx, therapy; STS, Society of Thoracic Surgeons; TAVR, transcatheter aortic valve replacement.
Clinical Guidelines Holmes et al4.3.2.3. PARTNER Trial Results
In the inoperable Cohort B patients with symptomatic
severe AS, TAVR substantially reduced all-cause mortality
by nearly 50% and the composite of all-cause mortality
and repeat hospitalization by 55% compared with standard
therapy at 1-year follow-up (Table 5). In addition, all
key secondary endpoints including patient function
significantly improved at 30 days and 1 year. TAVR was
associated with an increased risk for stroke and
procedure-related adverse events such as bleeding and vas-







All-cause death (%) 5.0 2.8
All-cause death or rehospitalization (%) 11.2 12.3
Event-free MACCE (%) 90.5 94.4
All stroke (%) 7.3 1.7
Major stroke (%) 5.6 1.1
All-cause death or major stroke (%)* 8.4 3.9
Major vascular complications (%) 16.8 1.1
Major bleeding (%) 20.6 3.9
Pacemaker insertion (%) 3.4 5.0
Echocardiograph
AVarea (EOA) (cm2) 1.5  0.4 0.8  0.2
Mean AV gradient (mm Hg) 11.1  6.6 33.0  12.5
Cohort B includes only nonsurgical candidates in whom ‘‘inoperability’’ was formally d
complication by 30 days by 1 cardiologist and 2 cardiothoracic surgeons. Data are based
Advisory Panel meeting on TAVR on July 21, 2011 (http://www.accessdata.fda.gov/cdrh_d
lished manuscripts. AV, Aortic valve; EOA, effective orifice area;MACCE, major adverse c
aortic valve replacement. *All-cause death or major stroke was not a predefined endpoint
e44 The Journal of Thoracic and Cardiovascular Surgwere treated all favored TAVR. Overall, the benefit from
TAVR in inoperable patients with symptomatic severe
AS greatly exceeds the risk.
In the high-risk Cohort A patients, TAVRwas noninferior
to AVR for all-cause mortality at 1 year (24.2% vs 26.8%,
hazard ratio: 0.93, 95% confidence interval: 0.71 to 1.22,
P ¼ .001 for noninferiority) (Table 6). AVR mortality at
30 days (6.5%) was lower than expected operative mortal-
ity (11.8%). Whether this discrepancy can be attributed to
chance alone (ideal outcomes with expert surgeons within







(N ¼ 179) P value
.41 30.7 49.7 <.001
.74 43.6 70.4 <.001
NR 65.4 47.1 .003
.02 11.2 4.5 .03
.04 8.4 3.9 .12
.12 33.0 50.3 .001
<.0001 17.3 2.2 <.0001
<.0001 28.4 14.4 <.001
.60 4.5 7.8 .27
ic endpoints
<.0001 1.6  0.5 0.7  0.32 <.0001
<.0001 12.5  10.3 44.4  15.7 <.0001
efined as greater than 50% predicted probability of mortality or serious irreversible
on Edwards Lifesciences’ briefing document for the U.S. FDA Circulatory Devices
ocs/pdf10/P100041b.pdf), and may show some discrepancies compared with the pub-
ardiac and cerebrovascular events; NR, not reported; Rx, therapy; TAVR, transcatheter
.
ery c September 2012
TABLE 6. Major outcomes at 30 days and 1 year in Cohort A of the PARTNER trial
Characteristic








(N ¼ 351) P value
Clinical outcomes
All-cause death (%) 3.4 6.5 .07 24.2 26.8 .44
All-cause death or rehospitalization (%) 7.2 9.7 .24 34.6 35.9 .73
All stroke (%) 5.5 2.4 .04 8.3 4.3 .04
Major stroke (%) 3.8 2.1 .20 5.1 2.4 .07
All-cause death or major stroke (%)* 6.9 8.2 .52 26.5 28.0 .68
Major vascular complications (%) 17.0 3.8 <.01 18.0 4.8 <.01
Major bleeding (%) 9.3 19.5 <.01 14.7 25.7 <.01
Atrial fibrillation (%) 8.6 16.0 <.01 12.1 17.1 .07
Pacemaker insertion (%) 3.8 3.6 .89 5.7 5.0 .68
Echocardiographic endpoints
AVarea (EOA) (cm2) 1.7  0.5 1.5  0.4 .001 1.6  0.5 1.4  0.5 .002
Mean AV gradient (mm Hg) 9.9  4.8 1.8  5.0 .16 10.2  4.3 11.5  5.4 .008
Cohort A includes patients determined to be at high operative risk defined as predicted operative mortality of15% and/or an STS risk score of10%. The STS risk algorithm is
based on the presence of coexisting illnesses in order to predict 30-day operative mortality. AV, Aortic valve; AVR, aortic valve replacement; EOA, effective orifice area; TAVR,
transcatheter aortic valve replacement. *All-cause death or major stroke was not a predefined endpoint.
Holmes et al Clinical Guidelines‘‘calibration drift’’ as surgical outcomes improve over time
is not clear. All neurological events (30-day major stroke,
3.8% vs 2.1%) and vascular complications (30-day,
11.1% vs 3.2%) were more frequent with TAVR. By con-
trast, major bleeding and new-onset atrial fibrillation were
more frequent with AVR. Improvements in echocardio-
graphic findings were similar in both groups, although para-
valvular regurgitation was increased with TAVR. The data
from this cohort further support TAVR as an acceptable al-
ternative to surgical AVR in selected high-risk operable
patients.
Of note, the 30-day mortality (generally thought to be
procedure-related) in Cohort A (3.4%) and Cohort B
(5.0%) was lower than the published SOURCE registry
mortality (8.5%), despite a relatively lower-risk patient
population enrolled in the latter (1-year mortality of
30.7% in Cohort B, 22.2% in Cohort A, and 18.9% in
SOURCE). This arguably raises questions about the gener-
alizability of the randomized trial data to clinical practice.
4.3.2.3.1. Quality of Life. The quality-of-life results from
Cohort B arm, the inoperable cohort, TAVR patients had im-
provement in the 6-minute walk performance compared
with baseline (P¼ .002), whereas standard therapy patients
did not (P ¼ .67).15 In addition, TAVR patients were less
symptomatic (New York Heart Association class), had re-
duced hospitalization stay, and improved physical function-
ing compared with standard therapy. In the high-risk cohort,
both New York Heart Association class and 6-minute walk
test favored TAVR at 30 days, but the differences were not
significant at 1 year. TAVR patients had shorter index hos-
pitalization length of stay (8 vs 12 days, P<.001). Quality
of life as assessed by disease-specific measures (Kansas
City Cardiomyopathy Questionnaire [KCCQ]) and byThe Journal of Thoracic and Cageneral health-related quality of life (Short Form-12 Health
Questionnaire) improved at 1, 6, and 12 months in the
TAVR group and were significantly higher than in the con-
trol arm (P<0.001). This supports that general and disease-
specific quality of life are improved with TAVR to 1 year
over standard care among inoperable patients122 (Table 7).
The quality of life results from the Cohort A arm of the
PARTNER trial were presented in November 2011. The
preliminary conclusions were that among patients with se-
vere AS who were at high risk for standard valve replace-
ment, both surgical and transcatheter AVR resulted in
substantial improvement in disease-specific and generic
health-related quality-of-life assessment over 1-year
follow-up, including KCCQ Summary Scale, SF-12 Physi-
cal, and SF-12 Mental tests. The benefits were greater at
earlier time points in the transfemoral TAVR group and
were equivalent at 1 year.123
4.3.2.3.2. Continued-Access Protocol. Upon completion of
the randomized PARTNER trial, patients have been al-
lowed to have access to TAVRunder a continued-access pro-
tocol. Enrollment in the randomized continued-access cohort
was initiated following completion of the enrollment for
PARTNER cohort B trial. From March to September 2009,
91 inoperable patients were enrolled—41 were randomized
to TAVR and 50 to standard care. Both short-term





group analyses were not conducted due to the small sample
size. Enrollment in nonrandomized continued-access cohort
was initiated in September 2009 after both cohorts ofrdiovascular Surgery c Volume 144, Number 3 e45
TABLE 7. Quality of life and symptom assessment in TAVR trials
Study population NYHA functional class 6-Minute walk Questionnaire Other
PARTNER B (trial) TAVR
vs placebo (multicenter;
N ¼ 358)15,122
More class I, II with TAVR at
1 year (74.8% vs 42.0%)
TAVR improved walk time
pre/post at 1 year; no
change in no-TAVR group
KCCQ; marked improvement
with TAVR at 1 year; SF12;
improvement in physical





PARTNER A (trial) TAVR vs
SAVR (multicenter;
N ¼ 699)124
More class I, II with TAVR at
30 days; no difference
between TAVR and SAVR
at 1 year
TAVR improved walk time at
30 days compared with
SAVR; no difference
between TAVR and SAVR
at 1 year
NR Shorter LOS with TAVR
HRQOL, Health-related quality of life; KCCQ, Kansas City Cardiomyopathy Questionnaire; LOS, length of stay; NR, not reported; QOL, quality of life; SAVR, surgical aortic
valve replacement; TAVR, transcatheter aortic valve replacement.
Clinical Guidelines Holmes et alPARTNERhad completed randomized enrollment. Over 600
patients with transfemoral TAVR are being followed cur-
rently in this cohort.
4.3.2.4. TAVR-Specific Clinical Issues
4.3.2.4.1. Stroke. Stroke is one of the major adverse events
associated with TAVR. Standardized criteria for theTABLE 8. Stroke
Stroke diagnostic criteria
Rapid onset of a focal or global neurological deficit with at least 1 of the
following: change in level of consciousness, hemiplegia, hemiparesis,
numbness or sensory loss affecting 1 side of the body, dysphasia or
aphasia, hemianopia, amaurosis fugax, or other neurological signs or
symptoms consistent with stroke
Duration of a focal or global neurological deficit 24 h; OR<24 h, if
therapeutic intervention(s) were performed (eg, thrombolytic therapy or
intracranial angioplasty); OR available neuroimaging documents a new
hemorrhage or infarct; OR the neurological deficit results in death
No other readily identifiable nonstroke cause for the clinical presentation
(eg, brain tumor, trauma, infection, hypoglycemia, peripheral lesion,
pharmacological influences)*
Confirmation of the diagnosis by at least 1 of the following:
Neurology or neurosurgical specialist
Neuroimaging procedure (MR or CT scan or cerebral angiography)




New focal neurological deficit with rapid symptom resolution (usually 1
to 2 h), always within 24 h
Neuroimaging without tissue injury
Stroke: (diagnosis as above, preferably with positive neuroimaging study)
Minor—modified Rankin score<2 at 30 and 90 daysy
Major—modified Rankin score 2 at 30 and 90 days
Reprinted with permission from Leon et al.96 CT, Computed tomography;MR, mag-
netic resonance. *Patients with nonfocal global encephalopathy will not be reported
as a stroke without unequivocal evidence based upon neuroimaging studies.
yModified Rankin score assessments should be made by qualified individuals accord-
ing to a certification process. If there is discordance between the 30- and 90-dayMod-
ified Rankin scores, a final determination of major versus minor stroke will be
adjudicated by the neurology members of the clinical events committee.
e46 The Journal of Thoracic and Cardiovascular Surgdefinition of stroke endpoints for TAVR clinical trials
have been published by the VARC (Table 8). The incidence
of stroke depends on the assessment technique used for as-
certainment. In the PARTNER Cohort A, the risk of clini-
cally apparent ‘‘major’’ stroke defined as modified Rankin
score 2 was 3.8% at 30 days and 5.1% at 1 year among
the TAVR group compared with 2.1% and 2.4%, respec-
tively, in the surgical group.124 In the PARTNER Cohort
B, the stroke risk was 5% with TAVR compared with
1.1% with standard therapy at 30 days and 8.4% versus
3.9% at 1 year.15 Using magnetic resonance imaging-
diffusion weighted imaging (MRI-DWI) studies, the
incidence of cerebral ischemic lesions post-TAVR has
been reported to be as high as 68% to 84% in some studies,
although clinically apparent stroke was reported in>4% of
cases.125-128 Thus, the clinical significance of these new
CMR-defined lesions post-TAVR is not clear.
Most stroke cases are due to thromboembolism from the
valve site or due to atherothrombotic emboli originating
from ulcerative plaque in the great vessels such as the aortic
arch. Such particles can be dislodged during catheter ma-
nipulation and embolize to the carotids or vertebrals to
cause occlusions of distal intracerebral branch arteries.
Other potential causes include hypotension associated
with rapid ventricular pacing or hemodynamic instability
during the procedure, and rarely due to aortic dissection
complicating TAVR. It is important to recognize that
many patients who have AS may also have other causes
for an ischemic stroke such as age, hypertension, diabetes,
or other cardiac conditions, including atrial fibrillation,
which is a potent risk factor for cardioembolic stroke.69 Dif-
ferentiating the cause of the stroke is not always easy, but
most trials and registries define strokes within 30 days of
an interventional procedure as attributable to the procedure.
After 30 days, other comorbid risk factors may account for
stroke, which might, therefore, not be attributable to the
prosthetic valve. Diagnostic evaluations are needed to as-
sess the neck and cerebral vessels, cardiac function, and
other potential causes of stroke in order to differentiate
the stroke subtype and embark on the best treatment toery c September 2012
Holmes et al Clinical Guidelinesprevent a recurrent stroke.129,130 Nearly two thirds of the
strokes related to TAVR at 1 year occurred within the first
30 days in PARTNER Cohort B (13/20), suggesting that
most events were likely procedure-related.15 The incidence
of stroke may lessen as patient selection becomes more re-
fined, delivery systems improve in their profile, and embolic
protection devices and protocol-driven antithrombotic reg-
imens are routinely used during TAVR.
4.3.2.4.2. Conduction Defects. Atrioventricular conduction
disturbances after TAVR are associated with many patient-
related and procedural-related factors, including preopera-
tive comorbid status, the degree and bulkiness of aortic valve
and annular calcification, interventricular septal thickness,
pre-existing electrocardiogram abnormalities, the depth of
prosthesis implantation, and the profile of the implanted
prosthesis.131,132 Unlike conventional AVR, where there
may be localized trauma due to decalcification of the
annulus and/or suture placement in the proximity of the
AV node or the bundles, TAVR may cause conduction
abnormalities through mechanical impingement of the
conduction system by the prosthesis.
The incidence of new left bundle-branch block and com-
plete heart block after TAVR ranges from 14% to 83% and
19% to 22%, respectively. Patients with pre-existing right
bundle-branch block may be at the highest risk for the de-
velopment of complete heart block and the need for subse-
quent pacing.133 The majority of conduction abnormalities
occur prior to actual valve implantation, with 46% occur-
ring during balloon aortic valvuloplasty, 25% during bal-
loon/prosthesis positioning and wire-crossing of the aortic
valve, and the remaining 29% during prosthesis expan-
sion.134 The incidence of complete heart block requiring
permanent pacemaker implantation has been higher with
the CoreValve (19.2% to 42.5%) than with the Sapien valve
(1.8% to 8.5%), potentially due to its larger profile and ex-
tension low into the LVoutflow tract. In the most recent UK
Registry, pacemakers were implanted in 24.4% of patients
receiving the CoreValve.
Overall, permanent pacemaker implantation rates with
the CoreValve, but not Sapien valve, are higher than con-
ventional surgical AVR rates of 1% to 10%. The need for
permanent pacemaker implantation occurs early postproce-
dure and rarely after hospital discharge. The need for per-
manent pacemaker implantation has no effect on survival,
both early at 30 days postprocedure and late at 1 year.135
Continuous postoperative electrocardiogram monitoring
should be performed in all patients early after TAVR proce-
dures. Patients with pre-existing or new conduction abnor-
malities and those receiving the CoreValve device may
require longer monitoring.
4.3.2.4.3. Vascular Complications. Vascular complications
are the most frequent adverse outcome of TAVR and areThe Journal of Thoracic and Caespecially common with transfemoral approach.136 These
complications relate to the large-caliber sheaths necessary
for device deployment, as well as severe atherosclerosis
of the arteries, which is common.137 Center/operator expe-
rience, the degree and location of vascular calcification,
vascular tortuosity, and sheath-to artery ratio are predictors
of major vascular complication.137,138 Major vascular
complications are classified in accordance with the
definitions provided by the VARC and include aortic
dissection, perforation, rupture, or bleeding requiring
significant blood transfusions, or additional percutaneous
or surgical intervention.96 Incidence of major vascular com-
plications ranges from 2% to 26%with transfemoral access
and is related to vessel size, tortuosity, and degree of aortoil-
iac occlusive disease and from 5% to 7% with transapical
access.107,109,111,116,139
Subclavian access may represent an alternative approach
in some patients in whom transfemoral or transapical direct
aortic access cannot be utilized. Subclavian artery injury is
rarewith such access although transient brachial plexus neu-
ropathy has been reportedwith this approach.140 As delivery
systems improve in their profile, the incidence of these com-
plications will lessen.136,141 Of note, left subclavian arterial
access for TAVR may not be appropriate in patients with
prior CABG with left internal thoracic arterial graft
because temporary interruption of blood flow in the left
internal thoracic artery may cause coronary insufficiency.
4.3.2.4.4. Patient Preferences. Informed consent requires
the patient and/or support system be appropriately
informed of the procedure benefits and risks, possess per-
sonal decision-making capacity, and ultimately be able to
make a voluntary decision. Older adults often rely on
trusted physicians, family, or friends to participate and
guide medical decision making at the point of medical
care. A central goal in this interaction is the exchange
of relevant, detailed information about treatment strate-
gies delivered in terminology that is understood by the pa-
tient and family. This patient-centric educational effort is
essential in providing the patient and family information
to facilitate interaction with the health care team, and pro-
mote personalized decision making for each patient. It is
important to remember that risk tolerance and patient ex-
pectations vary across many patient populations. Thus,
a thorough review of personalized risk/benefit profile is
essential for each patient undergoing an invasive
procedure.
4.3.2.4.5. Benefit/Risk Assessment. The complex task of
balancing the benefit and risk of TAVR depends upon accu-
rate information regarding prognosis for survival, morbid-
ity, and expected quality of life. Ideally, an accurate
validated model that predicts both in-hospital and long-
term outcome should guide this analysis, help educaterdiovascular Surgery c Volume 144, Number 3 e47
TAVR vs Sta
Benefit
• 190 deaths prevented •
• 218 hospitalizations prevented
• Shorter hospital stay





• 26 deaths prevented*
• 110 fewer major bleeding events
• 50 fewer atrial fibrillation cases*
• 4
• 1
• Shorter hospital stay





- 45 excess major strokes
419 excess hemorrhagic vascular events
- 151 major vascular events




- 27 excess major strokes
32 excess major vascular events
52 excess mod./severe AR
- 49 excess mod./severe paravalvular AR
FIGURE 4. Benefit/risk balance in the PARTNER trial. Data are shown
for every 1000 patients treated with TAVR instead of standard treatment
in Cohort B (above) or standard AVR in Cohort A (below). The excesses
listed are not mutually exclusive, because some patients had more than 1
event. Only data with statistically significant differences at 1 year of
follow-up are shown except for deaths* (P ¼ .44) and atrial fibrillationy
(P¼ .07) in Cohort A. AR, Aortic valvular regurgitation; AVR, surgical aor-
tic valve replacement; TAVR, transcatheter aortic valve replacement.
Clinical Guidelines Holmes et alpatients and their families, and effectively manage safety
tradeoffs and health care expenditure. Such a model would
include some assessment of the relative role of severe AS
versus comorbidity (eg, COPD in the etiology of symptoms
such as dyspnea). Although several risk models have been
developed for prognostication after cardiac surgery, they
are limited by modest performance with regards to discrim-
inatory ability, calibration, and face validity. It is not clear
whether these models for conventional cardiac surgery are
similarly predictive of outcome of patients being considered
for TAVR. An additional important issue relates to the lack
of a formal assessment of other aspects of treatment risk and
benefit (eg, gait, cognition, frailty) in these risk models.
Thus, better performing risk models are needed that include
a wide spectrum of prognostic variables using contempo-
rary data in relevant populations for a TAVR-specific risk
algorithm.
In TAVR candidates, the benefits of avoidance of ster-
notomy and cardiopulmonary bypass with its attendant
complications and prolonged recovery/hospitalization by
applying TAVR appear to come at the price of potentially
serious vascular and technical complications and in-
creased hazards of stroke and paravalvular AR
(Figure 4). For prohibitively high-risk inoperable patients,
such a tradeoff is acceptable given the documented
statistically-significant and clinically-important mortality
benefit and functional improvement. For high surgical
risk patients in whom mortality benefit has not been
proven, the findings present a dilemma, given that the ir-
reversible effects of stroke might be of greater potential
clinical significance in terms of long-term disability,e48 The Journal of Thoracic and Cardiovascular Surgpermanent dependency, and increased societal costs than
the complications of sternotomy and bleeding. Although
bleeding occurs acutely, is often overt, and has immediate
clinical impact leading to increased length of stay and re-
source utilization, a ‘‘causal link’’ to adverse long-term
clinical outcome remains unproven. Ultimately, the rela-
tive weights both patients and physicians assign to the
utility associated with these periprocedural hazards is
likely to impact individual case-based benefit/risk assess-
ment and decision making. Cost considerations are also
likely to materially impact the adoption of TAVR in treat-
ment algorithms for AS.
4.3.2.5. Medtronic CoreValve U.S. Pivotal Trial
The U.S. pivotal trial with the Medtronic CoreValve self-
expanding valve is currently enrolling patients at 40 sites
(NCT # 01240902). Patients are allocated into either an Ex-
tremeRisk cohort, similar to Cohort B inoperable patients in
the PARTNER trial or a High Risk cohort analogous to
PARTNER Cohort A. There will be 487 patients enrolled
in the extreme-risk group with an additional 100 patients
with inadequate iliofemoral access placed in a nested regis-
try of alternative access with either subclavian or direct aor-
tic approaches. TheHighRisk cohortwill enroll 790 patients
in a 1:1 randomization between TAVR and surgical AVR.5. INTEGRATION OF TAVR INTO CLINICAL
PRACTICE
5.1. Patient Evaluation and Management
5.1.1. Multidisciplinary Team
The creation of a multidisciplinary team that includes the
patient in the decision process in choosing the most appro-
priate form of treatment for AS including AVR (ie, surgical
or percutaneous) is essential. It is similar in concept to the
‘‘heart team’’ approach for CAD.142 Factors such as sex,
race, availability, experience, and institutional commitment
to managing very high-risk patients, technical skills, local
results, referral patterns, and patient preference all may
have an impact on the decision-making process and should
be taken into account by this multidisciplinary team. Ide-
ally, such a team would be comprised of the patient’s
primary cardiologist, cardiac surgeon, interventional cardi-
ologist, echocardiographer, imaging specialists—CT or
CMR, heart failure and valve disease specialist, cardiac an-
esthesiologist, nurse practitioner, and cardiac rehabilitation
specialists. Such a strategy would result in input from mul-
tiple skill sets with the goal being the best possible course of
therapy leading to the best possible clinical outcome for the
specific patient.
Localization of a heart team working together in a valve
clinic will help optimize the functions of the valve team.
Such a clinic should combine clinical cardiac care,ery c September 2012
Holmes et al Clinical Guidelinesadvanced imaging capability, and surgical consultation to
provide centralized assessment and treatment options for
complex valve disorders. Patients referred to a valve clinic
should be assessed by a cardiologist and a cardiovascular
surgeon to discuss the options for surgical intervention if in-
dicated. Prior diagnostic studies should be reviewed and ad-
ditional diagnostic imaging (echocardiography, TEE,
MDCT [multidetector computed tomography], CMR) per-
formed as clinically indicated. Overall, a valve clinic should
offer patients a personalized approach for the evaluation
and treatment of complex valve disorders with the availabil-




TAVR is appropriate currently only for a highly select
population and the valve team should systematically iden-
tify the characteristics that define that population with
most benefit and acceptable risk. These identification crite-
ria should be operationalized into practice and may evolve
over time with this new technology as new data become
available.
The inclusion and exclusion criteria in extant randomized
studies are generally appropriate for use in clinical practice
(Table 9). These vary somewhat, but there are some criteria
common to most studies. Some criteria can be precisely
identified with objective measurements, but many require
subjective estimates based on clinical judgment. These sub-
jective assessments are at least as important as the objective
determinations and necessarily create some variability in
the process of patient selection. The criteria presented
here are based on current technology and experience. As
technology improves and experience is gained, it is likely
that many of these criteria will change to expand TAVR to
different populations that will be optimally treated with
the next generation of devices. In addition, the arbitrary cri-
teria such as qualifying aortic AVA measurement within 45
days within the procedure will be modified and made more
flexible.
5.1.2.2. Specific Patient Subsets
5.1.2.2.1. Porcelain Aorta, Friable Aortic Atheroma, Radi-
ation Heart Disease. Occasionally, otherwise fairly
healthy candidates for AVR will have local factors such as
prior radiation therapy to their mediastinum and/or severe
calcific changes within their ascending aorta (‘‘porcelain
aorta’’) that add significant risk to a traditional open AVR.
Rarely, transesophageal echocardiography will reveal ad-
vanced atherosclerosis with mobile and pedunculated athe-
romata that also increase risk for stroke or a major embolic
event with traditional TAVR. Cases such as these areThe Journal of Thoracic and Caapproached individually and the correct approach is at
best an educated judgment on the part of the surgical
team. TAVR offers an alternative for the treatment of AS
when there is severe circumferential calcification (porcelain
aorta) or heavy atherosclerotic disease burden in the as-
cending aorta.143 Patients with extensive atherothrombotic
burden involving the ascending aorta should be approached
very carefully irrespective of whether either a transapical or
transfemoral procedure because of the potential for
embolization.
5.1.2.2.2. Very Elderly. Advanced age has important impli-
cations, as typically these patients have several comorbid
conditions (in addition to advanced age) that increase the
risk of AVR or TAVR. Functional status and comprehensive
assessment of comorbidities including CAD, history of
transient ischemic attack or stroke, chronic kidney disease,
and dementia should be performed. Finally, risk and benefit,
including prognosis of existing conditions, should be thor-
oughly discussed with the patient and family as part of
the initial meeting with the TAVR team and should include
a review of postprocedural complications that may extend
hospitalization. On the other hand, successful procedures
result in improvement in dyspnea, a heightened energy
level, and an overall improved quality of life. Life expec-
tancy can be prolonged, since the mortality of medically-
treated symptomatic severe AS carries a high mortality.
As noted above, symptoms usually improve following
valve replacement, but a caveat exists for elderly patients
regarding dyspnea and the presence of LVH. LVH is seen
in 54% of men and 81% of women with severe AS144-147
whereas men more often have less LVH, some LV
chamber enlargement, and some reduction in EF.
Occasionally women will have such severe diastolic
dysfunction that even when the afterload stress is relieved
by TAVR, elevated LV filling pressures may result in
persistent symptoms of shortness of breath. Since LVH
may eventually regress following TAVR, shortness of
breath may also eventually improve over several months
following valve replacement. Men, who tend to have
a greater degree of LV myocardial fibrosis and abnormal
LV collagen network patterns,148 may have more inherent
reduced contractility, so that relieving afterload with
TAVR may also not result in early or marked symptomatic
improvement.When discussing TAVRwith the very elderly,
they should be made aware that symptomatic improvement
may be delayed or minimal in some cases.
5.1.2.2.3. Frailty and Futility Versus Utility. As previously
discussed, the concepts of frailty and futility will assume
central importance in patient selection for TAVR by virtue
of the extensive comorbidities present in this population.
Frailty is an important and frequent condition in elderly pa-
tients and should be considered when dealing with invasiverdiovascular Surgery c Volume 144, Number 3 e49
TABLE 9. Patient selection: Inclusion and exclusion criteria in clinical trials
Inclusion criteria
1. Patient has calcific aortic valve stenosis with echocardiographically derived criteria: mean gradient>40 mmHg or jet velocity>4.0 m/s and an initial
AVA of<0.8 cm2 or indexed EOA<0.5 cm2/m2. Qualifying AVA baseline measurement must be within 45 days of the date of the procedure.
2. A cardiac interventionalist and 2 experienced cardiothoracic surgeons agree that medical factors either preclude operation or are high risk for surgical
AVR, based on a conclusion that the probability of death or serious, irreversible morbidity exceeds the probability of meaningful improvement. The
surgeons’ consult notes shall specify the medical or anatomic factors leading to that conclusion and include a printout of the calculation of the STS
score to additionally identify the risks in the patient. At least 1 of the cardiac surgeon assessors must have physically evaluated the patient.
3. Patient is deemed to be symptomatic from his/her aortic valve stenosis, as differentiated from symptoms related to comorbid conditions, and as
demonstrated by NYHA functional class II or greater.
Exclusion criteria (candidates will be excluded if any of the following conditions are present)
1. Evidence of an acute myocardial infarction1 month (30 days) before the intended treatment (defined as: Q-wave MI, or non–Q-wave MI with total
CK elevation of CK-MB  twice normal in the presence of MB elevation and/or troponin level elevation [WHO definition])
2. Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is noncalcified
3. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation>3þ)
4. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation, or mechanical heart assistance within 30 days of
screening evaluation
5. Need for emergency surgery for any reason
6. Hypertrophic cardiomyopathy with or without obstruction
7. Severe left ventricular dysfunction with LVEF<20%
8. Severe pulmonary hypertension and RV dysfunction
9. Echocardiographic evidence of intracardiac mass, thrombus or vegetation
10. A known contraindication or hypersensitivity to all anticoagulation regimens, or inability to be anticoagulated for the study procedure
11. Native aortic annulus size<18 mm or>25 mm as measured by echocardiogram*
12. MRI confirmed CVA or TIAwithin 6 months (180 days) of the procedure
13. Renal insufficiency (creatinine>3.0 mg/dL) and/or end-stage renal disease requiring chronic dialysis at the time of screening
14. Estimated life expectancy<12 months (365 days) due to noncardiac comorbid conditions
15. Severe incapacitating dementia
16. Significant aortic disease, including abdominal aortic or thoracic aneurysm defined as maximal luminal diameter 5 cm or greater; marked tortuosity
(hyperacute bend), aortic arch atheroma (especially if thick [>5 mm], protruding or ulcerated) or narrowing (especially with calcification and surface
irregularities) of the abdominal or thoracic aorta, severe ‘‘unfolding’’ and tortuosity of the thoracic aorta
17. Severe mitral regurgitation
AVA, Aortic valve area; AVR, aortic valve replacement; CK, creatine kinase; CVA, cerebrovascular accident; EOA, effective orifice area; LVEF, left ventricular ejection fraction;
MB, MB isoenzyme;MI, myocardial infarction;MRI, magnetic resonance imaging;NYHA, NewYork Heart Association; RV, right ventricular; STS, Society of Thoracic Surgeons;
TIA, transient ischemic attack; WHO, World Health Organization. *The boundaries of annulus size will continue to change in concert with changing device size.
Clinical Guidelines Holmes et alcare in older adults.149 Although it can have significant
overlap with disability and comorbidity, it is a distinct syn-
drome and is characterized by a vicious cycle of decreasing
muscle mass, energy expenditure, and malnutrition culmi-
nating in vulnerability to adverse events.150 In the PART-
NER trial, frailty was present in as many as 23% of
patients in Cohort B and 16% in Cohort A. Besides comor-
bidities, and frequently in combination with them, it is
likely to play a role in the assessment of the individual’s
candidacy for invasive care and therefore in withholding
any intervention in nearly one half of high-risk patients
with AS.151 It is important to consider that frailty may be
a reversible physiological phenotype in some cases, and
therefore it is premature to consider this a permanent char-
acteristic of the individual patient. To the extent that AS
may contribute to the declining health state, AVR or
TAVR may reverse frailty. In this case, frailty may be
a marker for treatment benefit. Conversely, if the individual
is frail from multiple other organ system declines, frailty
may be a marker of treatment risk.e50 The Journal of Thoracic and Cardiovascular SurgThe impact of frailty on the clinical course and outcome
of patients presenting with severe AS is beginning to be
investigated but is difficult to assess because of its multidi-
mensional phenotype and the lack of a clear and agreed-
upon assessment. The definition of frailty used in recent
studies ranges from the qualitative ‘‘eyeball test’’ to more
quantitative scores such as the Fried Frailty Index.150 A
simple test for defining frailty is a timed gait speed over 5
m. In a recent Canadian study,152 a time of>6 seconds as
a measure of frailty was found to be an independent predic-
tor of mortality compared with the STS risk algorithm
alone. As such, it has recently been added to the STS
database upgrade (Version 2.73, July 1, 2011) and will be
uniformly collected in patients undergoing cardiac sur-
gery.152 Future studies should aim at developing more reli-
able and reproducible ways of identifying frailty, as well as
incorporating these assessments in development of risk and
benefit prediction.
Futility is also an important consideration for TAVR.
There may be some patients in whom this procedureery c September 2012
Holmes et al Clinical Guidelinesshould not be performed because the clinical condition is
too far advanced; in these patients, even a successful tech-
nical procedure is futile and does not improve health
outcomes.
Therapeutic futility may be determined based upon: (1)
lack of medical efficacy, as judged by the patient’s physi-
cian; or (2) lack of a meaningful survival, as judged by
the personal values of the patient.153,154 Although
therapeutic futility may be invoked to justify denial,
limitation, or withdrawal of care, the threshold for
defining it is unclear, controversial, and often viewed
differently by different stakeholders. In the PARTNER
trial, the criterion for inoperability—used as a surrogate
for futility with regards to surgical intervention—was an
estimate of probability of death or serious, irreversible
morbidity 50% by a cardiologist and 2 experienced
cardiothoracic surgeons.15 Despite successful correction
of AS leading to an absolute 20% survival advantage, there
was still 30% mortality in the TAVR treatment arm at 1
year, mainly due to noncardiac causes. The key to treatment
in this group of ‘‘inoperable’’ patients is to define the ‘‘fu-
tility versus utility’’ treatment paradigm. Clearer definition
of comorbid conditions that adversely affect survival de-
spite successful valve implementation as well as quality
of life and health economic assessment in those ‘‘inopera-
ble’’ patients is crucial so that this therapy is appropriately
used in patients likely to benefit (utility) compared with
those unlikely to benefit despite successful therapy (futil-
ity). Although some might argue that it is inappropriate
and misleading to say that treatment is futile simply because
the probability that it will succeed is small, especially given
the substantial uncertainty in our ability to prognosticate in
individual patients and lack of validated tools that univer-
sally discriminate survivors from nonsurvivors of critical
illness, it is nonetheless important to define meaningful cut-
off points. This is particularly true when, in the course of
a progressive illness, continued use of resources other
than measures for comfort, is no longer reasonable, practi-
cal, or appropriate. Ultimately, these decisions must be
guided by what our society considers to be the inherent
value of human life and the resultant financial burden soci-
ety is willing to bear for the provision of modern public
health care.155
5.1.3. Care Plan in Candidates for TAVR
The health care team needs to be intimately involved in
discussions on risk/benefits including detailed information
on individualized risks for each patient and alignment of
quality-of-life expectations. Failure to understand and com-
ply with a plan of care may account for dissatisfaction with
procedural outcomes and potential rehospitalizations.156,157
One critical intervention to ensure effective care
coordination and transition is that of comprehensive plan
of care and educational material given to patient and/orThe Journal of Thoracic and Cacaregivers prior to the planned procedures, and again
during and after hospitalization. This process may
encourage full participation of the patient and family
about adherence to medication therapy and activity
recommendations. Transitions of care and follow-up will
be improved by discussion and written instructions re-
viewed with each patient including medications, timely
follow-up with the various health care professionals in-
volved with the patient’s ongoing care, and appropriate
postprocedural activities. The ongoing care and coordina-
tion with the cardiovascular care team may decrease likeli-
hood of readmission and improve overall adherence. Health
care providers should pay close attention to psychosocial
and socioeconomic issues that the patient and family face,
including access to care, risk of depression, and health
care disparities.158-160
5.1.4. Imaging Assessment
Imaging plays an essential role in patient selection and
procedural planning, performance, and follow-up.161 In
each of these steps, optimal imaging can help to enhance
successful outcome. There is variability in the specific im-
aging protocols preferred in individual institutions. This
variability is the result of institutional and individual expe-
rience and equipment, as well as the specific patient charac-
teristics to be considered.
5.1.4.1. Echocardiography
The following general recommendations can be made for
echo assessment of patients being considered for TAVR.
More detailed instructions can be found in a recent expert
consensus statement from the American Society of
Echocardiography and the European Society of
Echocardiography.161
5.1.4.1.1. Annulus Size and Cusp and Root Anatomy. Accu-
rate assessment of annular size is critical.Underestimation of
annular size could lead to selection anddeployment of avalve
which is too small, with risks of poor hemodynamics, para-
valvular regurgitation, and valve migration and embolism.
Overestimation of annular size and placement of a valve
that is too large can lead to other adverse outcomes, including
incomplete deployment (with both valvular and paravalvular
regurgitation) or catastrophic annular rupture. In general, all
TAVRs are designed to be deployed in annuli that are slightly
smaller than the prosthesis size. This oversizing is required
because the valves are sutureless and depend on radial force
to prevent dislodgement. For the initial Sapienvalves, the 23-
mm valve was designed for 18-mm to 22-mm annuli,
whereas the 26-mm prosthesis was designed for 21-mm to
25-mm annuli. The Sapien XT valve, with 23-mm, 26-mm,
and 29-mm sizes, is designed for annuli from 18 mm to 27
mm. The CoreValve has 26-mm, 29-mm, and 31-mm pros-
thesis sizes (using a different sizing convention from therdiovascular Surgery c Volume 144, Number 3 e51
Clinical Guidelines Holmes et alSapien valve) designed for annuli from 20 mm to 23 mm for
the 26-mm prosthesis, 24 mm to 27 mm for the 29-mm pros-
thesis, and 26 mm to 29 mm for the 31-mm annuli. Annular
dimensions can be measured with either TTE or TEE.162
With either modality, the annular anteroposterior diameter
is measured from a long-axis view. Care must be taken to
identify the true annulus, not overlying calcium. Measure-
ments are made in systole at the hinge point of the leaflets
into the LVOT with a trailing edge to leading edge conven-
tion. Because the annulus is often elliptical, optimal assess-
ment should includemeasurement of the transverse (coronal)
diameter, using the short-axis view, ideally with biplane TEE
approach or CT, which allows simultaneous long- and short-
axis interrogation of the annular plane.
5.1.4.1.2. Aortic Root Disease and Ascending Aortic Di-
mensions. Assessment of cusp and root anatomy is also
critical. The PARTNER trial excluded all patients with bi-
cuspid aortic valves for concern that such valves might dis-
tort the prosthesis, leading to paravalvular regurgitation.
Thus, TAVR in any nontricuspid valve would be considered
an off-label use, though successful treatment of bicuspid
valves has been reported.163 It is often difficult to determine
cusp anatomy in the densely calcified valves commonly
treated by TAVR. In this setting, CT or review of old echo-
cardiograms may allow better assessment of the underlying
anatomy. Pathology reviews have demonstrated progressive
increase with age in the proportion of trileaflet valves in se-
vere AS patients, from 15% in those under 60 years to 60%
over 70 years (72% for those over 80 years).2 Of note, this
study showed that even pathological examination cannot
determine cusp anatomy in some heavily distorted valves.
Several issues must be considered in assessing root anat-
omy and pathology. Care must be taken to assure that valve
deployment will not compromise the coronary ostia, either
from the device itself or from cusp calcification being
shifted and displaced into the coronary. In general, CT scan-
ning provides a more comprehensive assessment of the re-
lationship of the coronary arteries to the annulus and
valve leaflets, demonstrating an average annular–left coro-
nary artery distance of 13.4  3.2 mm and annular-right
coronary artery distance of 13.6 2.8 mm.164 Nevertheless,
echo, particularly TEE, can measure the distance from the
aortic valve annulus to the right coronary ostium. Since
the left coronary does not lie in a standard TEE or TTE im-
aging plane that intersects the annulus, measurement from
3D datasets may be a feasible approach for this.
Accurate assessment of the aortic root and tubular portion
is also important. The CoreValve Revalving System is de-
signed with a supra-annular location of the porcine pericar-
dial valve, located in the sinus of Valsalva. As a result, the
CoreValve nitinol frame has a longer length than conven-
tional surgical valves, ranging from 52 mm (for the
31-mm valve) to 55 mm (for the 26-mm valve) includinge52 The Journal of Thoracic and Cardiovascular Surgits deployment hooks. It is recommended that the upper di-
mensions of the tubular aorta measured at 45 mm above the
annulus be 40 mm for the 26-mm valve and 43 mm for the
29-mm and 31-mm CoreValve prostheses.
Preprocedural assessment of AR in TAVR candidates
should be governed by guidelines from the American Soci-
ety of Echocardiography.165 This assessment is based on
multiple parameters, including LV size, AR jet size and
morphology, AR pressure half-time, and diastolic flow re-
versal in the aortic arch. Patients with>3þ AR were ex-
cluded from the PARTNER trial and should be considered
relatively contraindicated for TAVR.
5.1.4.1.3. Three-Dimensional Echocardiography. Real-
time 3D TEE is an important modality for preprocedural
and intraprocedural assessment of TAVR patients.166,167
Similar to MDCT and CMR, it can help with precise
assessment of the aortic root and annulus, potentially
helping reduce the chance for prosthesis-sizing error in pa-
tients. However, multiple studies have demonstrated signif-
icant differences in dimensions of the aortic root and
annulus measured by 2D TTE, 2D TEE, 3D TEE, and
MDCT.166,167 Hence, it is imperative to realize that the
imaging technique utilized might impact TAVR size
selection and strategy. TEE, including real-time 3D TEE
can help evaluate the extent of and precisely locate the jet
of AR following prosthesis implantation.
5.1.4.2. Tomographic Imaging
5.1.4.2.1. Rationale for Tomographic Imaging. Optimizing
outcome relies heavily on image guidance for patient se-
lection, preprocedural planning, and intraoperative deci-
sion making.168 Correct positioning of the prosthesis
relative to the annulus is critical. If valve deployment is
too high, increased risk of paravalvular regurgitation, aor-
tic injury, coronary occlusion, or embolization of the pros-
thesis can occur. If positioning is too low, mitral valve
dysfunction, heart block, paravalvular regurgitation, or
embolization into the left ventricular cavity can occur.169
In addition, the relatively large delivery catheters cur-
rently required for valve insertion are associated with
the risk of vascular complications, necessitating assess-
ment of iliofemoral vasculature. This has led to the appli-
cation of 3D imaging approaches for TAVR, including CT,
CMR, 3D echocardiography, and C-arm CT162,166,170,171
(Table 10).
5.1.4.2.2. Multidetector Computed Tomography. MDCT
provides comprehensive assessment of the aortic root, ath-
erosclerotic burden, and course of the thoracoabdominal
aorta and its iliofemoral branches (Figure 5). MDCT in
the context of TAVR eligibility assessment has become rou-
tine in many large-volume centers.172ery c September 2012
TABLE 10. Potential approaches for imaging in TAVR
Preprocedural assessment
1. Assessment of aortic annular size and shape (CT, CMR, 2D and 3D
echocardiography)
2. Assessment of aortic valve for number of cusps, degree of
calcification and valve area by planimetry (CT, CMR, 2D and 3D
echocardiography)
3. Measurement of the distance between annulus and coronary ostia
(CT, CMR, 2D and 3D echocardiography)
4. Planning for precise coaxial alignment of the stent-valve along the
centerline of the aortic valve and aortic root (CT)
5. Assessment of aortic dimensions (2D and 3D echocardiography, CT
or CMR) and atherosclerosis (echocardiography, CT, or CMR)
6. Assessment of dimensions and atherosclerosis of iliofemoral vessels
(CT, MR, angiography)
Postprocedural assessment
1. Assessment of degree of aortic regurgitation (echocardiography or
CMR)
2. Assessment of cerebral embolization (cerebral MRI)
2D, 2-dimensional; 3D, 3-dimensional; CMR, cardiac magnetic resonance; CT, com-
puted tomography; MRI, magnetic resonance imaging; TAVR, transcatheter aortic
valve replacement.
Holmes et al Clinical GuidelinesMDCT systems with at least 64 detectors and a spatial
resolution of 0.5 mm to 0.6 mm are recommended. The spe-
cific scan protocols used for assessment vary but generally
include imaging of the aortic root and the thoracoabdominal
aorta and its iliofemoral branches. ECG-synchronized im-
aging of the aortic root is important to avoid image quality
degradation due to motion artifacts, and image reconstruc-
tion is performed at the desired phase of the cardiac cycle
(eg, a systolic 30% to 40% phase for valve area and annular
assessment). Using the retrospectively ECG-gated helical
acquisition, CT data can be acquired throughout the entire
cardiac cycle, enabling 4D image reconstructions for
evaluation of valvular function, albeit at the expense of
a higher radiation dose.173 Alternatively, prospectively
ECG-triggered axial CT data acquisition requires much
less radiation; however, images are acquired during a pre-
specified phase of the cardiac cycle and reconstruction in
other phases or 4D cine loops may not be reconstructible.174
However, protocols with newer generation scanners allow
prospective acquisition at a lower radiation dose with sub-
sequent display of cine loops.175 Although radiation expo-
sure is important to consider with any CT acquisition, it is
less a concern in the elderly patients currently considered
for TAVR.
Because a standard bolus of 80 mL to 120 mL of low-
osmolar iodinated contrast is necessary, the benefits versus
risks of iodinated contrast need to be carefully weighed.176
An alternative approach involves a pelvic scan after intra-
arterial contrast injection into the infrarenal abdominal
aorta (catheter left in place after cardiac catheterization) us-
ing a very low dose (15 mL) of contrast.177 If contrast ad-
ministration is not feasible, a noncontrast scan, althoughThe Journal of Thoracic and Canot optimal, still allows the assessment of overall vessel
size, calcification, and tortuosity.
As previously mentioned, analysis and measurement of
the annulus size and shape are crucial for procedural suc-
cess. Typical annulus measurements, obtained using 2D
TTE or TEE provide a single diameter measurement, as-
suming a circular annular orifice.178 In contrast, 3D CT
systolic reconstruction of the annulus orthogonal to the
center-axis of the LVOT allows for the assessment of mini-
mal and maximal diameter, circumference, and area mea-
surements.162,164,166,179-183 Indeed, these studies have
demonstrated that the LVOT is often oval, rather than
circular. Hence, multimodality imaging might improve the
accuracy of AV measurements and reduce the chance for
prosthesis-sizing errors in patients considered for TAVR.
Complete coronary assessment with MDCT is obviously
limited in the current population evaluated for TAVR be-
cause of the very high prevalence of advanced calcified dis-
ease, precluding precise assessment of luminal stenosis.
However, MDCT allows measurement of the distance be-
tween annulus and coronary ostia, which identifies patients
at risk for coronary occlusion during TAVR. Although no
definite criteria exist to exclude patients, a<10mm distance
might identify increased risk of coronary ostial occlu-
sion.184 In this setting, placement of a guidewire or balloon
catheter in the left main artery could be considered to ensure
access in case of complications.
Although echocardiography is used extensively to assess
the aortic valve, cine MDCT can provide incremental value
in its assessment, including number of cusps, especially in
cases of heavy calcification, where echocardiography can
be difficult. Also, cine MDCT can be used to perform
planimetry of the aortic valve.180,185
Optimal coaxial alignment of the stent valve along the cen-
terline of the aortic valve and aortic root is important during
positioning. Ascertainment of the right height to avoid too
high or too low placement is important to avoid AR and opti-
mize valve function.169 Although traditional assessment of
root orientation is performed using multiple invasive aorto-
grams in1or 2 orthogonal planes, double-obliquemultiplanar
MDCT reconstruction allows preprocedural prediction of the
aortic root angle.186,187 This potentially decreases the number
of aortograms required during the procedure, therefore
shortening both procedure time and contrast usage, and
improves precision of deployment. The emergence of
C-arm CT would further allow the incorporation of fusion
imaging in the catheterization laboratory.170
5.1.4.2.3. Cardiac Magnetic Resonance. Similar to MDCT,
CMR can also potentially provide comprehensive assess-
ment of the aortic valve, annulus, aortic root, course of
the thoracoabdominal aorta and luminal caliber of the ilio-
femoral branches, without the ionizing radiation. 2D ECG-
gated noncontrast cine CMR sequences across the aorticrdiovascular Surgery c Volume 144, Number 3 e53
FIGURE 5. Reconstructed multidetector computed tomographic images of the abdominal aorta and its pelvic branches demonstrating tortuosity and ex-
tensive calcific atherosclerosis. The extent and degree of peripheral arterial disease is essential in determining the feasibility and safety of transfemoral
approaches. In some patients with extensive disease, alternative approaches such as direct aortic, subclavian, or transapical procedures should be considered.
Clinical Guidelines Holmes et alvalve (even avoiding the calcium blooming commonly seen
on CT) and aortic root can provide a detailed assessment of
LV function, aortic annulus, valve, root, and coronary ostia,
similar to that obtained on MDCT.188 In addition, free-
breathing noncontrast navigator-gated 3D whole-heart
acquisition can also be obtained to mimic the volumetric ac-
quisition of a CT image.171 It also enables assessment of the
aortic root in addition to assessing the LVOT–aortic root an-
gulation and predicting imaging planes. The use of 3D
gadolinium-enhanced magnetic resonance imaging can pro-
vide precise luminal dimensions of the thoracoabdominal
aorta and its iliopelvic branches.189 In cases with renal in-
sufficiency, a navigator-gated, free-breathing, 3D noncon-
trast steady-state free precession sequence can be used to
assess luminal dimensions. However, CMR is not optimal
for assessment of aortic wall changes, especially dense aor-
tic calcifications, because it would lead to signal voids and
hence, appear dark. Postprocedural assessment of residual
aortic insufficiency by quantitative CMR might have a po-
tential role in TAVR patients.190 However, CMR is
a time-intensive technique, which could be a limiting factor,
particularly in older patients. In patients with tenuous renal
function, the benefits of gadolinium administration have to
be balanced against the risks of nephrogenic systemic fibro-
sis.191 In addition to the above-mentioned constraints, CMR
is not recommended in patients with pacemakers,e54 The Journal of Thoracic and Cardiovascular Surgdefibrillators, or intracranial aneurysm clips, although the
currently used valves are CMR compatible.
5.2. Procedural Performance
5.2.1. Role of Surgeon and/or Cardiologist
The central position of the heart team in optimizing TAVR
patient evaluation, procedure performance, and outcomes has
been emphasized. Candidacy for TAVRshould be determined
together by both the surgeon and cardiologist, ideally in an
established valve or structural heart disease clinic. During
procedural performance, both cardiologist and surgeon
should be active participants. There are several specific tasks
to be considered among others: (1) gaining access to the vas-
cular tree by either various transarterial sites or by the trans-
apical route; (2) crossing the stenotic aortic valve; (3)
balloon aortic valvuloplasty; (4) optimal positioning and
deployment of the aortic prosthesis; (5) achieving secure vas-
cular closure; (6) assessment and treatment of procedural-
related complications, which encompasses vascular access,
cardiac structure, coronary artery anatomy, and electrophysi-
ology issues; and (7) considerations for access for hemody-
namic support and the need for cardiopulmonary bypass
need to be determined by the cardiovascular (CV) surgeon
and team. Each of these tasks containswithin itmultiple com-
ponent parts, eg, the need for rapid ventricular pacing duringery c September 2012
Holmes et al Clinical Guidelineseither balloon aortic valvuloplasty or prosthetic deployment,
and identifying the optimal fluoroscopic position to be used.
The above-mentioned tasks often require different skill
sets. In the future, as training programs evolve with integra-
tion of cardiovascular surgery and interventional cardiol-
ogy, the roles of either or both specialties may change.
However, at the present time and for the foreseeable future,
both a surgeon and an interventional cardiologist should be
integrally involved with each procedure. Prior to the start of
each procedure, a specific team leader should be identified,
either the surgeon or the interventional cardiologist. That
individual should have overall supervision for the specific
case to optimize the procedure. The specific person identi-
fied will depend on the operator experience as well as the
unique characteristics and challenges of each individual
case; for example, the cardiovascular surgeon should be
the primary team member responsible for the surgical as-
pects of transapical and transaortic procedures or if a subcla-
vian cutdown is to be required. Interventional cardiologists
usually assume the lead operator position in transfemoral
procedures, whereas cardiothoracic surgeons usually lead
transapical procedures. The specific roles of the other indi-
viduals involved should be identified. Some will be shared,
eg, deciding what specific angle identifies the optimal fluo-
roscopic view for visualizing the plane of the aortic valve
for deployment. Other roles will involve just 1 individual,
eg, taking the team through the pre-and postprocedure
checklists and selection of the specific pacing algorithm
for deployment. It is important for all members of the
team to be present for all stages of the procedure.
The most important considerations are team-based care,
identification of a specific team leader, close communica-
tion, and preplanning for outlining management of potential
complications. Likewise postprocedure care is optimally
delivered on a multispecialty team care service similar to
a transplant service where all specialties are participatory
to achieve optimal patient outcomes.
5.2.2. Procedural Location
Procedural location will vary from institution to institution
related to several factors including resources currently
available in the facility. The specific location has important
physical implications, as well as personnel and equipment
implications. Optimal equipment requirements include
a state-of-the-art, large-field-of-view fluoroscopic imaging
system—preferably a fixed overhead or floor-mounted sys-
tem that has positioning capability rather than a portable
C-arm system. This system needs to have the ability to store
and review images and accommodate varying patient sizes.
A potentially important adjunct for this is the availability of
either biplane imaging or imaging programs that can automat-
ically help aid in the selection of orthogonal views for imag-
ing during positioning of the valve. Integration of TEE
echocardiographic images, particularly 3D capabilities, isThe Journal of Thoracic and Cahelpful; the availability of CTor CMR is a significant advan-
tage, particularly if image overlay is possible, which will be-
come more widely used in the future. Full catheterization
laboratory hemodynamic capability is also required for
hybrid rooms. Other resources required include present
cardiopulmonary bypass machines, perfusionists, and related
ancillary supplies with an inventory of interventional cardiol-
ogy equipment for balloon aortic valvuloplasty, coronary bal-
loons, stents, and 0.014-inch wires if coronary occlusion
occurs as a complication of device deployment. As vascular
access is critical, a variety of peripheral arterial balloons
and covered stents for treatment of peripheral vascular com-
plications such as iliac rupture, and a variety of vascular clo-
sure devices are also important for completion of the
procedure. The procedure location should also be fully capa-
ble of providing anesthesia services including advanced air-
way management, general anesthesia, full hemodynamic
monitoring, and administration of vasoactive agents into the
central circulation.
As can be seen, these requirements mandate specific
room sizes and configurations. Such a hybrid room may
be situated in a surgical suite or may be in a large modified
catheterization laboratory (approximately 800 square
feet) with appropriate air handling and air exchange modi-
fications. In the future, as procedures for the treatment of
a variety of structural heart and endovascular disease proce-
dures increase, it is anticipated that hybrid rooms will be-
come more standard of care for these team-based therapies.
Personnel requirements are also of great importance.
Personnel who are trained to deal with complicated
hemodynamics, the specific equipment to be used, and com-
plication management are critical. This has significant impli-
cations. For example, if the procedures are carried out in
a modified cardiac catheterization laboratory staffed by
cardiac laboratory personnel, although there would be expert
experience with percutaneous procedures and vascular com-
plications, if urgent cardiopulmonary bypass was required,
there may be undue treatment delays related to inexperience
with that specific procedure. On the other hand, if the proce-
dures are carried out in an operating room with limited cath-
eterization laboratory capabilities andpersonnel, the ability to
promptly address and treat a coronary or a vascular complica-
tion requiring immediate attention may be compromised.
Team-based training and care that includes complication
management remain a cornerstone.
5.2.3. Anesthetic Considerations for TAVR
Patients undergoing TAVR are at a high risk for procedural
complications, including hemodynamic collapse. Careful
planning and intraoperative anesthetic management can mit-
igate risk.67,192,193During thepreoperative evaluation, special
attention is paid to factors that may predict higher risk of
intraprocedural instability, in particular: depressed EF,
elevated pulmonary pressures, significant MR, incompleterdiovascular Surgery c Volume 144, Number 3 e55
Clinical Guidelines Holmes et alrevascularization, collateral dependent coronary circulation,
COPD, HF, and acute/chronic kidney disease. In patients
least likely to tolerate rapid ventricular pacing and
hypotension, preventive measures may be instituted194 and
steps taken to allow for rapid institution of cardiopulmonary
bypass. Rarely, elective bypass may be utilized. Routine sur-
gical antibiotic prophylaxis administered prior to surgical in-
cision or vascular access is warranted to decrease the risk of
wound infection and endocarditis.
TAVR is typically performed under general anesthesia
with central monitoring, using a pulmonary artery catheter
and transesophageal echocardiography. Single-lung ventila-
tion is not necessary for TA procedures. Although a tempo-
rary ventricular pacing wire can be placed through
a hemodynamic catheter, more commonly, a temporary
transvenous lead is passed through the femoral or subclavian
vein or, in the case of transapical procedures, sewn directly
on the epicardial surface. After a ventricular wire is passed,
thresholds are checked at a pacing of rate 10 to 20 beats/min
higher than the patients intrinsic rates. For placement of the
CoreValve, rapid pacing for device placement is not
required. Arterial pressure monitoring may be done via the
radial artery, but in the case of ipsilateral axillary bypass,
a plan must be made for additional monitoring either from
the contralateral radial or femoral artery. At least 1 large-
volume line is obtained peripherally or centrally. Immediate
access to a defibrillator device is necessary because ventric-
ular fibrillation can occur with manipulation of catheters
within the heart or with rapid ventricular pacing. This may
be best accomplished with preapplied defibrillator pads
connected to the defibrillator before starting the procedure.
Steps are required to prevent significant hypothermia,
and these are often similar to those used in off-pump
CABG. The room is heated, fluid warmers are used, and
some type of underbody heating system (either forced air
or fluid) is generally used. This is important because a lim-
iting step in early extubation of these patients is often the
time needed to warm them following the procedure.
Communication in this multidisciplinary approach is the
key word for intraoperative success. The importance of
training a dedicated team cannot be overemphasized. Fre-
quent changes of personnel will dilute the learning curve.
Standard doses of anesthetic, sedative, and narcotic analge-
sic agents may need to be reduced on the basis of the age
and frailty of the patient.195 Intraoperative challenges may
be encountered even before induction. Use of ultrasound
for venous access is beneficial to prevent hemorrhage and
complications associated with placement of central line.
Unless otherwise indicated, volume status needs to be
supplemented as the patients in this age group are usually
volume depleted. Generally, 1.0 L to 1.5 L of fluid are re-
quired, but a combination of pulmonary artery pressures,
central venous pressure, and echocardiographic evaluation
can guide tailored therapy. Severely underfilled ventriclese56 The Journal of Thoracic and Cardiovascular Surgmay pose an additional problem to guidewire/applicator de-
vice insertion in these hypertrophied ventricles. Patients
with severe concentric LV hypertrophy and intravascular
volume depletion may exhibit a rapid and sustained deteri-
oration of hemodynamic status in response to ventricular
pacing, rapid ventricular pacing, intracardiac guidewire or
catheter manipulations, or balloon aortic valvuloplasty. In
patients with low cardiac output and those with more than
moderate PH, inotropes such as milrinone or dobutamine
may be considered prior to the procedure, with the goal of
obtaining a cardiac index of at least 1.8 L/min/m2. Inhaled
nitric oxide or inhaled epoprostenol should be available for
the treatment of severe PH and right ventricular failure.
Avoidance of prolonged hypotension is perhaps the most
important step in preventing hemodynamic collapse. The cy-
cle of hypotension, subendocardial ischemia, low output and
further hypotension with ultimate ventricular fibrillation is
best avoided as treatment is difficult once these events occur.
Maintenance of ameanpressure of>75mmHg (or systolic of
at least 120 mm Hg) is advisable before initiation of rapid
ventricular pacing. The frequency and duration of rapid ven-
tricular pacing episodes may need to be limited to allow
enough time between episodes to permit recovery of circula-
tory function in patients with limited hemodynamic reserve.
In patientswith a slow recovery of spontaneous circulation af-
ter ventricular pacing, pre-emptive therapy with vasopressor
therapy such as norepinephrine, epinephrine, or phenyleph-
rine as an intravenous infusion or as incremental intravenous
boluses may be important to treat hypotension and facilitate
recovery after rapid ventricular pacing. Hypertension may
be dangerous and increase the risk of bleeding and ventricular
rupture, especially during transapical TAVR.
Anticoagulation therapy is usually initiated after inser-
tion of the regular sheaths and prior to placement of the
large sheath into the vasculature, and repeated to maintain
an activated clotting time (ACT) of>300 seconds. Heparin
anticoagulation can be reversed by the administration of
protamine sulfate on a milligram to milligram neutraliza-
tion dose, although it may not be necessary to reverse hep-
arin anticoagulation for transfemoral TAVR if there is
a minimal risk of surgical bleeding. A transvenous pacing
wire should be secured in position in patients with postpro-
cedural interventricular conduction abnormalities, at high
risk for heart block, or with heart block until it is determined
whether a permanent pacemaker is necessary.196
Although general anesthesia is generally used for transap-
ical procedures, some experienced institutions are perform-
ing transfemoral implantation with conscious sedation.197
With this approach, with conscious sedation, the patient is
awake and spontaneously breathing without an artificial air-
way. Intraoperative TEE for procedural guidance may be
difficult or impossible if TAVR is performed under con-
scious sedation. Adequacy of ventilation and oxygenation
should be continuously assessed during conscious sedationery c September 2012
Holmes et al Clinical Guidelinesand qualified personnel and equipment to perform intuba-
tion of the trachea, provide airway protection, and adminis-
ter mechanical ventilatory support should be immediately
available to detect and treat acute respiratory failure in pa-
tients managed during TAVR with conscious sedation.
5.2.4. Vascular Access
Placement of TAVR is accomplished via femoral artery,
subclavian artery, or the aorta. The Sapien valve may be
deployed by major transvascular access as well as transapi-
cally, whereas the CoreValve uses only major transvascular
access.110 Careful evaluation of the patient’s atherosclerotic
load and location, arterial size and tortuosity, and presence
of mural thrombus are required for the best possible deliv-
ery site. There are specific advantages and disadvantages
to each vascular access approach. Selection of the optimal
route requires consideration of specific patient anatomy
and the specific device to be used.
5.2.4.1. Cardiopulmonary Bypass Requirement
Cardiopulmonary bypass is infrequently (<5%) required
for support during the valve implantation due to cardiac de-
compensation as a consequence of cardiac tamponade, coro-
nary occlusion, severe acute AR, aortic rupture, or acute
aortic dissection. With experience, and excellent hemody-
namic and anesthetic management, this requirement is rarely
necessary. Accessory cannulation sites in the femoral vessels
or with an adjunctive axillary graft and venous cannula
should be considered if femoral access sites are not suitable.
Risk of vascular compromise, injury, or particulate embolism
should be weighed with the risk of cardiac support needs.
5.2.4.2. Percutaneous or Cutdown Access
Both percutaneous and cutdown access approaches are
used; there are advantages and disadvantages to each. Com-
plications with access in this high-risk and generally older
population are frequent. Decisions about access technique
and site depend on the degree and severity of atherosclero-
sis, vessel size, specific prosthetic device to be used, and the
heart team’s experience.136-138,198 Use of percutaneous
approaches preferentially occurs when access sites are
relatively large and free of significant atherosclerotic
disease. Less favorable vessels may require cutdown,
often with placement of axillary, iliac, or aortic insertion
grafts or conduits to provide access sites. Percutaneous
insertions are occasionally converted to open repair or
hybrid repairs, utilizing percutaneous closure devices and
surgical techniques as needed.199
5.2.4.3. Deployment Technique
The goals of deployment are to avoid hemodynamic com-
promise while obtaining a stable valve, positioned without
coronary obstruction, interference of mitral valve function,
conduction system impingement, or overhanging native
aortic leaflets, and avoidance of aortic root complicationsThe Journal of Thoracic and Ca(rupture and dissection). There are several approaches to
the aortic valve, which can be broadly categorized as retro-
grade or antegrade.
Retrograde passage is generally performed via the femo-
ral artery. There are obvious limitations in patients with pe-
ripheral arterial disease or small vessels. Additional,
reported retrograde options include the axillary approach
and direct ascending aortic puncture. A femoral approach
is used in the vast majority of retrograde deployments, start-
ing with either a standard percutaneous femoral arterial ac-
cess or a surgical exposure of the artery. A series of dilators
is employed, under fluoroscopic vision, to reach the size of
the deployment sheath. The sheath is passed into the body
of the thoracoabdominal aorta. Crossing the aortic valve
is accomplished using standard interventional techniques,
and a stiff wire exchange is performed, with redundancy
in the LV cavity to prevent loss of position. Care must be
taken to avoid damage to the LV, resulting in perforation.
The transapical approach is the only currently available
antegrade approach, and equipment is only available for
this approach for the Sapien valve. Access is obtained via
a left anterior thoracotomy, which is made after localization
of the apex by fluoroscopy or TTE. After entering the pleural
space, digital inspection can further localize the position of
the apex and a 2-inch to 3-inch segment of rib may be re-
sected to facilitate exposure. To reduce postoperative pain,
soft tissue retractors are preferred to heavy metal retraction.
The proper site of puncture is on the left ventricular apex,
which is more anterior and proximal than the anatomic car-
diac apex. TEE is of great value in helping to localize the
apex of the LV. Either 2 concentric purse-string sutures or 2
mattress sutures are placed with felt buttress. Puncture is
made and a 0.035-inch guidewire is passed through the native
valve. A balloon catheter may help facilitate wire placement
by avoiding themitral subvalvular apparatus. After the guide
wire is placed in the ascending aorta, a coronary catheter such
as a JR-4 can be used to guide the wire into the descending
aorta, and thewire is exchanged for a stifferwire (super or ex-
tra stiff). The deployment sheath is then passed to a depth of 3
cm to 4 cm, following which, balloon aortic valvuloplasty of
the native valve is performed prior to valve implantation.
Amore recent approach that has gained interest and accep-
tance is the direct aortic or transaortic approach. This ap-
proach is being employed with both the balloon expandable
and self-expanding techniques. The access is through either
an upper partial sternotomyor a second or third right intercos-
tal space minithoracotomy. Concentric felt pledgeted rein-
forced purse-string sutures are placed in the ascending aorta
at least 5 cm above the valve. A guidewire is then placed ret-
rograde across the valve, and balloon aortic valvuloplasty and
valve deployment performed similar to the other access tech-
niques. The advantages of this approach include the short dis-
tance from the aortic valve, allowing optimal control and
enhanced surgeon comfort level with a technique they arerdiovascular Surgery c Volume 144, Number 3 e57
FIGURE 6. Midesophageal long-axis TEE view showing the proper posi-
tioning of a sapien valve (black line*) across the aortic annulus prior to bal-
loon deployment. Note that approximately half the valve is above and below
the annulus. Note also the difficulty of imaging due to shadowing from the
prosthesis and annular and mitral valve calcification, as well as a prominent
reverberation artifact, emphasizing the need for thorough training prior to
providing procedural guidance. LA, Left atrium. *Visible as black line.
Clinical Guidelines Holmes et alalready using routinely for cardiopulmonary bypass cannula-
tion as compared with the left ventricular apex approach. An-
other possible advantage is a less painful incision than with
a left anterior thoracotomy at a lower interspace. Disadvan-
tages include manipulation of the ascending aorta with possi-
ble embolization of atherosclerotic debris when disease is
present. Current-generation delivery systems are being mod-
ified for this approach.200
5.2.4.4. Balloon Expandable Versus Self-Expanding
Prostheses
There are significant differences between the balloon-
expandable and self-expanding valves. Balloon-expandable
valves, such as the Sapien, cannot be collapsed once ex-
panded. Self-expanding, nitinol-based valves such as the
CoreValve can be partially deployed and repositioned to
some extent. The promise of recapture and repositioning
newer nitinol-based valves offer significant potential advan-
tages in reducing complications from malpositioning. Both
valves must be ‘‘oversized,’’ but the CoreValve in particular
seems to work best when the valve is somewhat underex-
panded. Risks of overaggressive sizing include leaflet
dysfunction and annular or aortic rupture.110
5.2.5. Imaging During TAVR
The mainstay of intraprocedural imaging is fluoroscopy
and angiography for device placement. TEE is an impor-
tant adjunct to this and is used at the operator’s discretion.
The role of intraoperative rotational CT scan is currently in
evolution. TEE is used for both transfemoral and transap-
ical deployment, but with transfemoral procedures increas-
ingly being performed under local anesthesia combined
with conscious sedation,197 the role of TEE in this setting
may decrease, though imaging around the time of valve de-
ployment in this setting is possible201 and transnasal TEE
with smaller probes may allow prolonged monitoring with-
out general anesthesia, though clearly with significant
compromise in comparison to standard TEE. TTE may
also be used for guidance, though image quality is limited.
Similarly, intracardiac echocardiography has been re-
ported for TAVR guidance, though imaging capabilities
are much less than TEE.202 Personnel performing TEE
guidance of TAVR, whether cardiologists or anesthesiolo-
gists, must be fully trained in the full spectrum of transeso-
phageal and intraoperative echo with special emphasis on
the aortic valve and associated structures.203 Training
guidelines indicate the need for involvement in 300 intra-
operative studies, 150 as an operator.203 Additional train-
ing is necessary to become familiar with the specifics of
TAVR. Frequent changes of the personnel performing
TEE guidance dilutes the learning curve and is not recom-
mended. Patients undergoing TAVR tend to be elderly, un-
stable, and have multiple comorbidities, and thus attention
must not be diverted from critical anesthesia management.e58 The Journal of Thoracic and Cardiovascular SurgIt is possible for the attending anesthesiologist to provide
echocardiographic procedural guidance, but in many situ-
ations, such guidance will need to be provided by a dedi-
cated cardiologist or anesthesiologist not distracted by
clinical anesthesia needs.
5.2.5.1. Recommendations for TEE Guidance for Patients
Undergoing TAVR
The following brief recommendations can be made for
TEE guidance of patients undergoing TAVR. More detailed
instructions of procedural echocardiography can be found
in a recent expert consensus statement from the American
Society of Echocardiography and the European Society of
Echocardiography.161
1. Guidewire placement: After confirming annular size for proper de-
vice selection, TEE can help with guidewire placement. This is par-
ticularly important in transapical TAVR, wheremanual dimpling of
the apex can be visualized and guidewire passage through the AV
can be confirmed, avoiding the submitral apparatus or the hyper-
trophied septum.
Valve placement: TEE can be very helpful in the correct placement
of the valve prosthesis, though fluoroscopy is commonly used for lo-
calization. It is critical to understand the landmarks of the valve
when mounted on the guiding catheter. For the Sapien valve,
roughly half of the device should be above and below the aortic an-
nulus (Figure 6). For the CoreValve, TEE should confirm that the
nitinol stent is well within the borders of the calcified native annulus.
Visualizing the valve during the time of rapid pacing and balloon in-
flation (for the Sapien valve) or deployment of the CoreValve pro-
vides an immediate verification of correct valve placement. If the
valve is placed using fluoroscopic guidance, the TEE probe mustery c September 2012
FIGURE 7. Mixed AR. Central and paravalvular AR following TAVR deployment in a biplane long- and short-axis TEE view. A1 and A2 are trivial para-
valvular leaks, whereas B is a trivial central regurgitation, all of which are negligible. C is a more severe paravalvular leak, which was ameliorated by a sec-
ond valve inflation. Ao, Aorta; AR, aortic regurgitation; LA, left atrium; LV, left ventricle.
Holmes et al Clinical Guidelinesbe partially retracted during that time to facilitate positioning or the
fluoroscopic view can be changed.
2. Postdeployment assessment: A particular concern for periprocedural
imaging relates to assessment of AR that is complicated by the com-
mon frequency of paravalvular leaks and shadowing from the pros-
thesis (Figures 7 and 8). This assessment must be made very rapidly
in the procedure room (to allow possible reballooning or even
deployment of a second valve if the AR is severe and cannot be
controlled otherwise). It is critical to distinguish between valvular
and paravalvular regurgitation and to determine whether it
is severe enough to require immediate intervention. Small
paravalvular leaks are often visualized due to the widespread
irregular calcification in the native valves that leave gaps between
the annulus and the prosthesis. If the leaks are punctate in cross
section, with jets that do not extend beyond the LVOT and without
visible proximal convergence zones above the prosthesis or flow
reversal in the aortic arch, then no intervention is needed (Figure 7,
jets A1 and A2). If not, and velocity aliasing is seen superior to the
prosthesis with AR extending beyond the LVOT, then reballooning
or a valve-in-valve approach may be appropriate (Figure 7, jet C).
Mild central valvular regurgitation is commonly seen after valve de-
ployment, which frequently resolves with removal of the guidewire
and/or a rise in central aortic pressure (Figure 7, jet B). An inade-
quately deployed transcatheter valve may have crimped leaflets
with more significant valvular AR, which dictates reballooning.
Rarely, 1 of the leaflets may remain stuck in the open position, result-
ing in torrentialARwithmarkedaorticflowreversal anda short pres-
sure half-time (Figure 8).204 In such a case, gentle probing with a soft
guidewire or catheter may free up the stuck leaflet; if not, immediate
placement of a second transcatheter valve should be considered. This
will be less of an issue with newer generation valve designs.
Postdeployment echocardiography commonly discloses small areas of
paravalvular or central valvular leak. Most commonly, these origi-
nate around areas of extreme leaflet calcification, particularly at the
commissural areas. If significant, these may be treated with repeat
ballooning of the prosthesis to further expand it to close paravalvular
leaks or inadequate noncircular deployment. A small additional
amount of fluid (1mL)maybe added to the systemprior to reballoon-
ing to insure complete inflation.110,205-210 For CoreValve, indicationsThe Journal of Thoracic and Caare similar—significant paravalvular leak with AR and
underexpanded prosthesis (assessed by TEE and/or fluoroscopy).
There are a number of other complications that must be recognized
immediately after TAVR if poor clinical outcome is to be averted.
Persistent hypotension may result from occlusion of a coronary
artery by the device or displaced calcium. This can be recognized
by characteristic regional hypokinesis, best appreciated from the
transgastric view and possibly by evaluating flow in the coronary
arteries themselves. Global dysfunction with preserved coronary
flow may reflect persistent depression from rapid pacing and
balloon inflation, requiring inotropes and possibly intra-aortic coun-
terpulsation or full bypass. Finally, hypotension may result from
LVOTobstruction following theabrupt fall inafterload, requiringvol-
ume,negative inotropes, andvasopressors.Otheretiologies suchas se-
vere MR, dislodgement of the AV prosthesis, pericardial tamponade,
RV perforation from the pacemaker lead, air embolism, vascular ac-
cess bleeding, and aortic dissection must be considered. Although
TEE is very helpful for initial device placement and deployment, it
is in the setting of hemodynamic instability that TEE is essential to
rapidly diagnose these complications.
5.2.5.2. Balloon Dilation and Size
Prior to passage of the valve, predilation of the annulus is
performed. Standard techniques of percutaneous balloon
aortic valvuloplasty are employed, with rapid pacing during
inflation. Radiographic contrast opacification of the root
during maximal inflation may provide useful information
when the location of the coronary ostia in relation to the an-
nulus and the leaflet calcification of any other aortic root pa-
thology is concerning and requires further delineation. The
valvuloplasty balloon size used is generally 20 mm to 23
mm, depending on the size of the annulus.110,211,212
5.2.5.3. Rapid Pacing
Rapid ventricular pacing is generally required for deploy-
ments with balloon-expanding devices. The goal is to createrdiovascular Surgery c Volume 144, Number 3 e59
FIGURE 8. Severe AR. Long-axis TEE view showing severe AR following TAVR deployment (A), confirmed by flow reversal in the descending aorta (B).
Short axis imaging (C and D) demonstrates that this is due to failure of the leaflet in the left coronary position (arrow) to close in diastole, ultimately treated
by deploying a second valve inside this one. Ao, Aorta; AR, aortic regurgitation; LA, left atrium; LV, left ventricle.
Clinical Guidelines Holmes et ala transient reversible decrease in ventricular ejection,
thereby reducing forces leading to valve migration during
deployment. Typically, this requires pacing at a rate of
160 to 220 beats/min. Ideally, there should be a decrease
in systolic pressure to<70 mm Hg, with a pulse pressure
<20 mm Hg. Pacing is accomplished by either transvenous
or, less frequently, epicardial electrodes. Reducing the num-
ber and duration of pacing runs is important in this tenuous
patient population to prevent instability.110,213
5.2.5.4. Experience With TAVR
An important issue in evaluating the results of TAVR is
standardization of definitions for success, as well as effi-
cacy. The VARC Consortium has proposed the definitions
for device success, combined safety endpoint at 30 days,
and the combined efficacy endpoint at 1 year or longer
(Table 11).96 Application of these standard definitions
will facilitate comparability and analysis of outcome be-
tween different registries and studies. Another importante60 The Journal of Thoracic and Cardiovascular Surgissue on outcomes as well as learning curves relates to the
experience of the center, patient selection criteria, and the
expert onsite technical support provided by the companies
in each case. For example, the UK TAVR experience docu-
mented similar results with proctored and nonproctored
cases, as well as the first 20 cases versus continued cases
in each center. This finding must be considered in light of
the fact that the review of potential cases is influenced by
the experience that other operators and centers have gained.
The presence of the industry representatives in the proce-
dures is also an invaluable asset in recognizing the potential
for complications and treatment of same. These 2 back-
ground issues enhance the chance of success and may
have contributed to the accelerated learning curve.115
Compared with patients who underwent TAVR early after
its introduction, patients treated more recently have
benefited from shared experiences, more careful patient
selection, advances in equipment and technique, and
expanded operator experience. Prior reports haveery c September 2012
TABLE 11. Composite endpoints
Device success
 Successful vascular access, delivery and deployment of the device and
successful retrieval of the delivery system
 Correct position of the device in the proper anatomical location
 Intended performance of the prosthetic heart valve (aortic valve area
1.2 cm2 and mean aortic valve gradient, 20 mm Hg or peak velocity, 3
m/s, without moderate or severe prosthetic valve AR)
 Only 1 valve implanted in the proper anatomical location
Combined safety endpoint (at 30 days)
 All-cause mortality
 Major stroke
 Life-threatening (or disabling) bleeding
 Acute kidney injury—stage 3 (including renal replacement therapy)
 Periprocedural MI
 Major vascular complication
 Repeat procedure for valve-related dysfunction (surgical or
interventional therapy)
Combined efficacy endpoint (at 1 year or longer)
 All-cause mortality (after 30 days)
 Failure of current therapy for AS, requiring hospitalization for
symptoms of valve-related or cardiac decompensation
 Prosthetic heart valve dysfunction (aortic valve area 1.2 cm2 andmean
aortic valve gradient 20 mm Hg or peak velocity 3 m/s, OR
moderate or severe prosthetic valve AR)
Reprinted with permission from Leon et al.96 AR, Aortic regurgitation; AS, aortic
stenosis.
Holmes et al Clinical Guidelinesdemonstrated a steep learning curve with TAVR using the
CoreValve and Sapien valves.214-217 Whether improved
operator experience alone can improve certain outcomes
more than others remains unclear.
Since its introduction, increasing experience with the
CoreValve TAVR revealed a trend of improved combined
safety endpoint at 30 days from 30% to 17%, predomi-
nately driven by a reduction in life-threatening periproce-
dural bleeding complications occurring from TAVR.215
The most recent UK experience115 identified a 30-day mor-
tality of 5.8%. Furthermore, there was a significant reduc-
tion in cerebrovascular complications. Despite these
trends, all-cause and CV mortality at 1 and 2 years remain
high. Experience using the Edwards Sapien valve, on the
other hand, revealed that, in 1 analysis, procedural experi-
ence was an independent predictor of 30-day mortality.214
The overall combined 30-day mortality decreased with in-
creased experience, 10.5% to 8.5%. Procedural success
rates also improved from 92.6% to 97.8% with time, pre-
dominately in the transfemoral approach, 89.3% to 98.8%.
Overall, consistent with other percutaneous therapies, the
evidence demonstrates that procedural success and mortal-
ity rates improve with experience, whereas periprocedural
complications are reduced. The introduction of smaller
valve platforms introduces some uncertainty in defining
whether the improved outcomes are solely related to the op-
erator’s experience. Nonetheless operational volumes of
given individuals and centers are critical to consider.The Journal of Thoracic and CaCurrent training protocols attempt to accelerate the learning
curve by utilizing experienced proctors and didactic teach-
ing, represented in both the PARTNER and CoreValve tri-
als. If the learning curve can be truncated, procedural
outcomes may continue to improve even as more operators
enter this clinical arena. Specific criteria regarding operator
and center training and experience are the focus of a multi-
societal credentialing document.218
5.3. Complication Management
Complications with TAVR are fairly common due to both
the complexity of the procedure, as well as the morbidity of
the patients being treated (Table 12). This has led to devel-
opment of new tools and techniques to manage these
complications.219
5.3.1. Shock, Low Cardiac Output Post-TAVR
The noncompliant hypertrophied ventricles in these pa-
tients are very susceptible to myocardial ischemia. The
combination of anesthesia, rapid pacing, volume shifts,
and brief periods of no cardiac output have made hemody-
namic shock and low cardiac output a not infrequent occur-
rence during and immediately after deployment.
The need for careful management of systemic pressure,
inotropic support, and optimal ventilation to avoid and mit-
igate PH is clear. In patients at extreme risk for hemody-
namic instability (ie, those with low EF, collateral
dependent coronary circulation, or PH), elective cardiopul-
monary bypass (CPB) has been used to facilitate the proce-
dure. Not infrequently, IABP support may be required to
bridge these patients to adequate cardiac output. Also
rare, but reported, is occlusion of coronary ostia by deploy-
ment (approximately 1% of cases). These may be addressed
at times percutaneously, but may require CPB support for
brief periods to allow recovery. Using a combination of
these techniques, cardiac failure as a cause of death in
TAVR has been rare.109,220-224 Rarely, ‘‘suicide’’ LV can
occur and must be looked for. This occurs in patients with
combined AS and subaortic stenosis or severe LV
hypertrophy and cavity obliteration.109,224,225 The
situation is exacerbated by diuresis and inotropes and is
instead managed with volume expansion and beta blockade.
5.3.2. Annular Rupture
Annular rupture is a rare but devastating complication of
TAVR. Predisposing factors include bulky and dense calci-
fication, small sinotubular junction, smaller annular size,
aggressive balloon predilation, and possibly porcelain
aorta. Once seen, mortality is high. Management can in-
clude decisions for comfort care and sedation, attempts at
medical management with pericardial drainage and auto-
transfusion of smaller leaks, and emergent conversion to
open operation, which makes it even more important to de-
fine and plan for or against this possibility in patients in
a ‘‘high-risk’’ substrate.226rdiovascular Surgery c Volume 144, Number 3 e61
TABLE 12. TAVR complications and management
Complication
Management options depending on the clinical condition, hemodynamic status, and
number of options available
Shock, low cardiac output  Careful systemic pressure management, inotropic support, IABP, or CPB
Occlusion of coronary ostia  PCI or CABG
Significant annular rupture  Pericardial drainage, autotransfusion, conversion to open surgical closure.
 If no other options, care and sedation
Ventricular perforation  Pericardial drainage, autotransfusion, conversion to open surgical closure.
Paravalvular aortic regurgitation  Postdeployment balloon dilation
Central valvular aortic regurgitation  Usually self-limited, but may require gentle probing of leaflets with a soft wire or catheter
 Delivery of a second TAVR device
Heart block  Pacemaker implantation
Device malposition
Device embolization
 Deployment of overlapping 2nd valve
 Urgent endovascular or surgical management




 Catheter-based, mechanical embolic retrieval
 Aspirin, anticoagulants
 Reversal of anticoagulation, correction of coagulopathy
Major bleeding  Hemodynamic support, blood transfusion
Vascular complications  Urgent endovascular repair/surgery
Acute kidney injury  Supportive care
 Maintain optimal fluid status
Each of the management options mentioned should be at least considered in the treatment of these complications. CABG, Coronary artery bypass graft; CPB, cardiopulmonary
bypass; IABP, intra-aortic balloon pump; PCI, percutaneous coronary intervention.
Clinical Guidelines Holmes et al5.3.3. Post-TAVR Aortic Regurgitation
Post-TAVR AR must be characterized as to its location,
severity, and cause and should integrate both central and
paravalvular origins to estimate overall volumetric impact.
Central regurgitation is generally a result of improper valve
deployment or sizing. Heavy guidewires through the valve
can cause a substantial leak by holding a leaflet open, and
full evaluation of central leak can only be undertaken
once these wires are removed. Overhanging leaflet material
can change the diastolic flow pattern and lead to improper
leaflet closure. Damage to the leaflets can occur during
crimping; significant central AR requires rapid consider-
ation of a valve-in-valve deployment.
Paravalvular leaks of varying degrees are common.
These are generally caused by inadequate inflation of the
prosthesis or by calcific deposits that prevent the valve
unit to properly seat and seal within the annulus. Acute
leaks may respond to repeat ballooning the valve to obtain
a better seal and more expansion. Predisposing factors in-
clude eccentric calcification and heavy irregular calcific de-
posits within the annular area, and incorrectly sized
prostheses. In addition, an increased LVOTangulation in re-
lation to the aorta, and a valve seated less deeply in the
annulus predispose to paravalvular leak. Paravalvular regur-
gitation is quite common immediately post-TAVR, occur-
ring at an incidence of 85%. At 1 year, up to 75% still
have mild or more paravalvular regurgitation, and one third
have more than mild regurgitation.
The incidence of residual mild or moderate AR (þ1 and
þ2) is significantly higher in TAVR patients comparede62 The Journal of Thoracic and Cardiovascular Surgwith surgical procedures, whereas hemodynamically severe
postprocedural AR (þ3 and þ4) is rare. Experience has
demonstrated that aortic paravalvular regurgitation after
self-expanding TAVR devices can be reduced by sufficient
balloon aortic valvuloplasty prior to deployment of a percu-
taneous prosthesis for self-expanding valves. Occasionally
in heavily calcified valves, repeat balloon dilation after
valve deployment is needed to fully expand the prosthesis.
Post-valve dilation can be performed safely with a slightly
oversized balloon, without causing significant structural
damage to the prosthesis. Appropriate preprocedural plan-
ning utilizing both echocardiography and CT for annular
analysis is important in order to avoid undersizing of the
valve compared with the annulus because this can also
cause significant paravalvular regurgitation.
Acute postprocedural regurgitation requires continued
surveillance because regurgitation may change in the subse-
quent days post-TAVR. The self-expanding properties of
the stent in the CoreValve prosthesis may reduce the grade
of paravalvular AR or recoil from the compressive forces of
the heavy calcification on either prosthesis may worsen the
degree.227,228 Clinical concern about the impact of
paravalvular regurgitation after TAVR is prudent, given
the findings that after surgical AVR, patients with
moderate-severe or severe AR develop chronic volume
overload that can lead to left ventricular remodeling/dys-
function and increase the risk for hemolysis. At the present
time, there is not sufficient long-term follow-up after TAVR
to understand the clinical significance of paravalvular
regurgitation and whether the severity of paravalvularery c September 2012
Holmes et al Clinical Guidelinesregurgitation progresses with time. However, it is clear that
postprocedural regurgitation is associated with adverse out-
comes.109,225 There are no reported cases of hemolysis with
TAVR despite paravalvular AR.
5.3.4. Post-TAVR Heart Block
TAVR is associated with a variable incidence of complete
heart block and/or need for pacemaker
implantation.132,227-231 This is much more common in
CoreValve recipients.227-231 Preoperative conduction
delay is associated with an increased incidence of
permanent pacemaker implantation as well. Although
heart block occurs usually early after TAVR, it may be
delayed up to 30 days. Enhanced surveillance for this
complication is important, particularly if the patients are
dismissed early following the procedure.
5.3.5. Post-TAVR Device Migration/Malposition
Rarely, TAVR devices will become malpositioned or mi-
grate. In the self-expanding models, they can be moved to
some degree until fully deployed. The balloon-expandable
models do not enjoy this degree of flexibility with position-
ing. A malpositioned valve may be ‘‘unstable’’ or may emb-
olize. If the valve is unstable, rapid placement of a second
overlapping valve may salvage the procedure. Valves em-
bolizing distally may occasionally be extracted in the aorta
and a second device implanted. Ventricular embolization re-
quires urgent surgery.185,232,233
5.3.6. Ventricular and Vascular Perforation
Ventricular perforation is a rare complication of transfe-
moral TAVR. Its management is similar to that for this com-
plication during percutaneous balloon aortic valvuloplasty,
with pericardial drainage and autotransfusion or conversion
to open closure. Large-vessel aortoiliac injury similarly is
uncommon, but if present, can be managed in most cases
by introduction of a covered stent. Some operators place
a guidewire down the leg from the contralateral femoral ar-
tery for rapid access and control. Readiness for vessel rup-
ture with occlusion balloon cannot be overemphasized.
Preparation for this complication is critical with preplan-
ning. It is best managed by avoiding it. Careful maintenance
of a good wire position and use of a stiff wire with a soft tip
are helpful in prevention of perforation during TAVR.2345.4. Postprocedural Care
5.4.1. Postprocedural Recovery
Designated units for postprocedural recovery are imper-
ative for optimal care and better outcome of this group of
high-risk patients undergoing TAVR.221 Although the par-
ticulars of postprocedural care will vary from institution
to institution and country to country, as well as with the ma-
turity of the TAVR program, the principles of care remainThe Journal of Thoracic and Cathe same that these complex patients should be treated in
postprocedural units experienced with both cardiac surgical
and interventional cardiology procedures.
5.4.1.1. Recommendations for Procedural Care After TAVR
1. Immediate or early extubation, early mobilization, and meticulous
attention to the many potential complications in this elderly, frail
group of patients.
2. Post-anesthetic care unit (PACU) or intensive care unit (ICU). There
should be a common care pathway with all patients cared for in the
same setting so that the care teamis conversantwith the carepathway.
The criteria for weaning in a fast-track concept are as follows:
a. Adequate core temperature of>36C
b. Hemodynamically stable
c. No active bleeding from drainage site
3. The care is somewhat different for transapical and transfemoral pa-
tients. Prevention of postoperative hypertension and hypertension
upon tracheal extubation is crucial in patients undergoing transapical
TAVR todecrease the riskof bleeding or ventricular rupture. Patients
undergoing transapical TAVR also require postoperative analgesia
for thoracotomy incisional pain and management of thoracostomy
tube drainage and subsequent thoracostomy tube removal. Transfe-
moral TAVR patients require supine positioning until femoral vascu-
lar access sheaths are removed and hemostasis has been achieved.
Patients undergoing direct aortic and subclavian approaches also
need to be carefully monitored for any mediastinal/thoracic bleeding
withparticularattentionpaid toavoidingpostoperativehypertension.
4. The monitoring includes vital parameters including fluid balance
therapy, renal status, and atrioventricular conduction system. Ade-
quate hydration and avoidance of early diuretic administration is im-
portant to minimize renal failure. Completion of perioperative
surgical antibiotic prophylaxis, resuming preoperative medications
such as beta blockers, and initiation of prophylaxis for venous throm-
boembolism should be addressed within the first 24 hours after oper-
ation. A painmanagement regimen should be initiated immediately if
necessary after operation in the postprocedural unit and may consist
of intercostal nerve block, infiltration of the wound with local anes-
thetics, narcotics, or non-narcotic analgesics. Epidural analgesia is
not normally required for transapical TAVRbecause the thoracotomy
incision is limited and satisfactory postoperative pain control can be
achievedwithparenteral orpatient-controlledanalgesics. Patientsun-
dergoing transfemoral TAVR should be evaluated for lower extremity
vascular insufficiency, groin hematoma, retroperitoneal bleeding, and
femoral artery pseudoaneurysm formation in the instrumented limb.
5. When stable, patients should be transferred to a telemetry unit with
hemodynamic and electrocardiographic monitoring capability. The
duration of monitoring will depend on the patients response to
TAVR and the specific prosthesis used. There are differences in
the need for permanent pacemaker implantation between the Ed-
wards Sapien and Medtronic CoreValve device with rates being
lower with the former; accordingly, longer electrocardiographic
monitoring may be required after implantation of the latter.132 De-
pending on institutional protocols, patients should be discharged
from the hospital after a final examination with TTE. Antiplatelet
therapy with aspirin and clopidogrel is recommended to decrease
the risk of thrombotic or thromboembolic complications if there
are no contraindications to these medications.2355.4.2. Hemodynamic Assessment
Echocardiographic assessment early after TAVR gener-
ally reveals a favorable hemodynamic response, with therdiovascular Surgery c Volume 144, Number 3 e63
Clinical Guidelines Holmes et alpresence of a significantly lower mean transvalvular gradi-
ent and a larger effective orifice area (EOA), usually 10
mm Hg and>1.5 cm2, respectively. Techniques used for as-
sessment of aortic valve performance vary. The use of mea-
surements of the left of the LVOT diameter and velocity
immediately proximal to the stent has been
emphasized.236 At short- and long-term follow-up, percuta-
neously implanted valves provide sustained improvements
in hemodynamic performance with slightly lower mean
transvalvular gradients and larger EOAs than surgically im-
planted valves, either stented or stentless.237
Postprocedure hemodynamic assessment is particularly
important to exclude potential prosthesis complications.
Transcatheter aortic valves differ, not only in design, but
also in implantation technique from surgical AVR. TAVR
preserves the native calcified aortic valve compared with
surgical AVR, which requires that the native valve be re-
moved prior to prosthesis implantation. The native valve
and annular calcification may potentially prevent the adher-
ence of the prosthesis to the aortic wall, whereas low pros-
thesis deployment into the LV outflow tract may lead to
incomplete and/or irregular expansion of the prosthesis, as
well as paravalvular prosthetic leak.
An additional concern is severe patient–prosthesis mis-
match, which is defined as an effective orifice area index
0.65cm2/m2.238 Patient–prosthesis mismatch in surgical
AVR is associated with a reduction in functional status
and increased morbidity and mortality at short-term and
long-term follow-up.239,240 The stent in TAVR prosthesis
is thinner than that of the stented valves employed for
surgical AVR, minimizing the obstruction to blood flow
and reducing the incidence of patient–prosthesis
mismatch. Whether reduced rates of patient–prosthesis
mismatch will translate to improved functional status and
improved survival remains to be defined.
5.4.3. Atrial Fibrillation
The incidence of new-onset atrial fibrillation (AF) after
successful TAVR ranges from 0.6% to 8.6%.15,124,132,241
However, over 25% of patients undergoing TAVR have
pre-existing AF. Continuous postprocedural electrocardio-
gram monitoring should be performed for at least 3 days
in all patients after transcatheter therapy. Management of
atrial fibrillation post-TAVR is based on the ACC/AHA/
ESC guidelines for management of atrial fibrillation.242
5.4.4. Treatment of Stroke
The treatment of a stroke will depend on the subtype of
stroke diagnosed by brain imaging, timing of the event after
any procedure, and the severity of the neurological deficit. A
large intracerebral hemorrhage could call for reversal of any
anticoagulants and correction of any coagulopathy with
fresh-frozen plasma or other transfusions.243 The diagnosis
of an acute ischemic stroke with moderate to severee64 The Journal of Thoracic and Cardiovascular Surgneurological deficits may require thrombolysis or mechani-
cal clot retrieval depending on the size, location, and
whether any major intracerebral artery is occluded. An in-
hospital stroke within 8 hours of the onset of neurological
symptoms usually requires urgent consultation by a stroke
neurologist or neurosurgeon. Angiography and stroke inter-
vention may be recommended for large and/or disabling
strokes. These treatments are generally available at compre-
hensive stroke centers. Typical embolic strokes in this set-
ting are the result of calcific emboli. If the stroke is the
result of thromboembolism, local rt-PA may be considered
although bleeding risk in this elderly population is very high.
Minor strokes, small infarcts on brain imaging, or the ab-
sence of any evidence of any major cerebral vessel occlu-
sions can usually be treated with aspirin.244 If atrial
fibrillation is present, then institution of an oral anticoagu-
lant program is warranted.129 If any intracardiac thrombus
is detected, then early institution of heparin followed by
oral anticoagulants is suggested.63 When the patient is sta-
ble, other diagnostic evaluations should be done to evaluate
for other potential causes of stroke, including vascular imag-
ing to detect any extracranial carotid or vertebral stenosis or
intracranial occlusive disease, echocardiography, and Holter
monitoring. If no definite source of cardiac embolism is de-
tected, then long-term treatment with antiplatelet options to
prevent recurrent stroke may be instituted, which include
aspirin, extended-release dipyridamole, and clopidogrel.1295.5. Long-Term Care
5.5.1. Role of Primary Cardiologist
The long-term care of the patient after TAVR will be
mainly guided by the primary referring cardiologist. In con-
trast to patients undergoing surgical AVR, patients undergo-
ing TAVR tend to be older, with more severe comorbidities
and lower functional status, mandating more frequent cardi-
ology follow-up.
The role of the primary cardiologist is to:
1. Prescribe and monitor medical therapy for concurrent
cardiovascular disease, including hypertension, atrial fi-
brillation, heart failure, CAD, and peripheral and cere-
brovascular disease, as well as diabetes and dyslipidemia.
2. Prescribe and monitor antithrombotic and/or antiplatelet
therapy as recommended for the prosthetic aortic valve
and concurrent conditions such as coronary stents or
atrial fibrillation.
3. Monitor cardiac and TAVR function with periodic clini-
cal evaluation and echocardiography.
4. Surveillance for and treatment of early and late
procedural-related complications
5. Maintain close communication with the implanting phy-
sicians if complications occur that may be related to the
procedure.ery c September 2012
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The patient should be followed closely by the implanting
physician team for the first 30 days after TAVR to diagnose
and follow any procedural complications. Evaluations
should include a post-TAVR baseline echocardiogram and
ECG (to document any conduction abnormalities) occur-
ring during that time period. After 30 days, a suggested
schedule for follow-up by the primary cardiologist is noted
in Table 13.
Follow-up is then continued at the first 6 months, at 1
year, and annually thereafter. The frequency of follow-up
evaluations should be increased if there is significant post-
TAVR paravalvular leak or any change in clinical status
or echocardiographic findings. As experience grows with
TAVR, the frequency of echocardiography assessment
will likely decrease towards that of surgical AVR, deemed
appropriate every 3 years.245 Additional diagnostic studies
may be considered as clinically warranted, including evalu-
ation for coronary disease if symptoms are present.
5.5.3. Hemodynamic Evaluation
Hemodynamic evaluation should be performed by echo-
cardiography as indicated in Section 5.5.2 above. Invasive
measurement of LV and aortic pressure is not routinely
needed unless there are unresolved questions, discrepancies
between echocardiographic and physical examination find-
ings, or other unresolved clinical issues.
5.5.4. Interaction of Co-Treatments
Given the frequency of coexisting conditions, multiple
antiplatelet or anticoagulant strategies may be required.
For example, some patients may be receiving antiplatelet
therapy for a coronary stent or antithrombotic therapy for
atrial fibrillation. This is complicated by the fact that most
patients undergoing TAVR are elderly and often have co-
morbidities that increase bleeding risk. It is prudent to
avoid, if possible, the use of multiple anticoagulant thera-
pies. In patients treated with warfarin, a direct thrombin in-
hibitor, or Factor Xa inhibitor, it is reasonable to continue
low-dose aspirin, but other antiplatelet therapy should be
avoided, if possible.
5.5.5. Management of AR
AR after TAVR typically is paravalvular and most often
only mild or mild to moderate in severity. At 1-year
follow-up, 13% of patients have no AR, with only traceTABLE 13. Recommended patient follow-up post-TAVR
Timing post-TAVR Clinical evaluation Echocardiography
30 days X X
6 months X
1 year X X
Annually thereafter X X
TAVR, Transcatheter aortic valve replacement.
The Journal of Thoracic and Caor mild regurgitation in 80% of patients.15,124 These
patients do not require any specific therapy for AR other
than medical therapy for concurrent hypertension and
periodic echocardiography monitoring as described above.
Moderate or severe AR is present after TAVR (even after
interventions during the procedure to reduce AR severity) in
about 12% of patients at 30 days and 7% at 1-year
follow-up.15,1245.5.5.1. Recommendations for Managing Severe AR After
TAVR
1 When severe AR is present after TAVR, treatment is similar to native
valve AR as detailed in the ACCF/AHA valvular heart disease guide-
lines.63
2 With acute severe AR or chronic severe AR with symptoms of heart fail-
ure, surgical AVRmay be considered if the patient is a surgical candidate
and surgical risk is acceptable. Other options include placement of a sec-
ond TAVR within the leaking prosthesis (‘‘valve-in-valve’’).6. TECHNOLOGY EVOLUTION
Next-generation devices promise the potential for im-
provements, offering expanded clinical utility with ad-
vances that include: lower profile delivery catheters,
more accurate positioning, reduced paravalvular leak, and
ability to either reposition or even retrieve (Table 14).246
Many of the new device technologies utilize a self-
expandable, high radial strength repositionable prosthesis
consisting of pericardial tissue on a nitinol frame. Two ad-
ditional valves have recently received approval for com-
mercial sale in Europe. The JenaValve (JenaValve
Technology, Munich, Germany) and Acurate Valve (Syme-
tis, Inc., Lausanne, Switzerland) are both delivered cur-
rently via a transapical approach.
Other valve designs currently in early clinical studies in-
clude Portico Valve (St. Jude Medical, St. Paul, Minn), Di-
rect Flow Medical (Direct Flow Medical, Santa Rosa,
Calif), and Sadra Lotus Valve (Sadra Medical, Los Gatos,
Calif). Other new designs include flexible sealing mem-
branes aimed at more optimal conformation to the calcified
native annulus to reduce paravalvular leaks. New valve de-
signs and materials can also provide the possibility of new
prosthesis technology. The Lutter valve was created in an
effort to create a more physiological heart valve by utilizing
tissue engineering.247 The PercValve (Advanced Biopros-
thetic Surfaces, San Antonio, Tex) uses nanotechnology in
its elastic nitinol frame and leaflets. These leaflets are de-
signed to allow for the growth of endothelial cells, essen-
tially converting it to a tissue valve. Initial animal studies
have shown complete endothelialization of the e-nitinol
leaflets within 10 days and may eliminate the need for anti-
coagulation.248 A final novel approach involves anchoring
the prosthesis by using an injectable polymer that cures in
position to maintain the implant permanently in place.rdiovascular Surgery c Volume 144, Number 3 e65























No No No 2003 No Balloon: 16
Self: 12
Direct Flow Direct Flow
Medical
Polymer-injected Pericardium Polymer Yes No No 2006 No 22
Lotus Sadra Medical Self-expandable Pericardium Nitinol Yes No No 2007 No 21
JenaValve JenaValve
Technology
Self-expandable Pericardium Nitinol Yes No No 2007 Yes 28
Heart Leaflet Heart Leaflet
Technologies
Self-expandable Pericardium Nitinol Yes Yes No N/A No 16
Lutter N/A Self-expandable Tissue
engineered




Self-expandable e-Nitinol e-Nitinol No No No N/A No 10
Portico St. Jude Self-expandable Pericardium Nitinol Yes Yes Yes 2011 No 22
Acurate Symetis Self-expandable Pericardium Nitinol Yes Yes Yes 2009 Yes 28
Modified from Chiam and Ruiz.94 CE, Conformite Europeenne, a mandatory conformity for products placed on the market in the European Economic Area; FIM, first in man; N/
A, not applicable; TAVR, transcatheter aortic valve replacement.
Clinical Guidelines Holmes et alThe outcome with these new technologies will be the focus
of multiple registries and then randomized trials.
7. APPLICATIONS IN NEW PATIENT
POPULATIONS AND NEW STUDY DESIGNS
As experience is gained and technology evolves, the pa-
tient population best served with TAVR is likely to change,
and 3 areas that merit specific consideration are the ‘‘valve-
in valve’’ technique for patients with dysfunctional aortic
bioprostheses, the use of TAVR in patients with stenotic bis-
cupid aortic valves, and application to lower-risk surgical pa-
tients. Other patient populations, such as those with chronic
or end-stage renal disease, may also be candidates for this
technology and will be the subject of future investigations.
7.1. Valve-in-Valve
Patients with dysfunction of a conventional aortic pros-
thesis present therapeutic challenges. Although repeat oper-
ation can be considered, an attractive option is to use
a TAVR procedure in which the device is deployed within
the previously placed bioprosthesis.209,249-254 In multiple
small series, transcatheter aortic valve-in-valve implanta-
tion appears to be a safe option for the management of bio-
prosthetic valve failure in patients at high risk for
reoperative conventional AVR. In this setting, coronary
anatomy should be carefully defined in order to minimize
the possibility of coronary obstruction by the transcatheter
prosthesis.209,220,250,255 In addition, valve-in-valve proce-
dures require a large enough bioprosthetic valve inserted
at the index operation to prevent patient prosthetic mis-
match with the TAVR valve.e66 The Journal of Thoracic and Cardiovascular Surg7.2. Bicuspid Aortic Valve
The asymmetric valvular anatomy often seen with a bi-
cuspid aortic valve theoretically predisposes to a noncircular
expansion of the TAVR device, thereby creating an in-
creased risk of paravalvular regurgitation.256
Because of this concern, the presence of a bicuspid aortic
valve is considered a relative contraindication to TAVR.
Since bicuspid aortic valve patients have generally been ex-
cluded from major TAVR trials, there is little clinical expe-
rience in this area. Several centers, however, have achieved
reasonable success in selected bicuspid aortic valve patients
with AS.163,256,257 It should be noted that in the Canadian
bicuspid aortic valve experience, moderate paravalvular
leaks occurred in 2 of 11 patients, and another patient
experienced late device migration.256 Bicuspid aortic valve
patients with bulky leaflets, markedly asymmetric valvular
anatomy, and significant aortic incompetence appear to
have a higher risk of suboptimal device seating. Whether
new valve designs, perhaps those with self-sealing mem-
branes, will improve device performance in this group re-
mains to be determined.
7.3. Lower-Risk Populations
Data from the STS Registry indicate that approximately
10% of patients undergoing AVR have an STS score 8
and therefore would be potential candidates for TAVR using
current selection criteria. There has been interest in expand-
ing the potential group of candidates for TAVR to include
patients with an STS score 4. This would broaden to
25% the number of patients who might be treated with
TAVR rather than AVR. There has been concern about the
potential for ‘‘selection creep,’’ with more lower-riskery c September 2012
Holmes et al Clinical Guidelinespatients treated with TAVR. This should be avoided until
more evidence-based data become available on the outcome
of TAVR versus AVR in these patients. The planned and on-
going trials evaluating both the Sapien and the CoreValve in
lower-risk populations will be of central importance in iden-
tifying subsequent utilization of this technology in ex-
panded patient groups.8. INTRODUCTIONOF TAVR INTOPRACTICE: U.S.
VERSUS EUROPEAN PERSPECTIVE
8.1. U.S. Perspective
The U.S. perspective reflects the fact that TAVR approval
required a randomized controlled trial, the full extent of
which has just now been published.124 This contrasts with
Europe where 5 new valves or iterations of current valves
are already in relatively widespread clinical use. Accord-
ingly, from the U.S. perspective, the rollout of this technol-
ogy is a key issue. This rollout is influenced by the societal
beliefs in a free market; convenient and timely access to
medical care; patient and physician expectations; as well
as return on investment by companies and institutions alike.
These latter issues have led to the proliferation of advanced
cardiovascular facilities, which could complicate the rollout
of new-device strategies such as TAVR. For example, the
state of California alone has 125 facilities that perform per-
cutaneous coronary intervention, the county/city of Los
Angeles has 33 cardiovascular surgical and primary ST-
elevation myocardial infarction centers. The Dallas–Fort
Worth Metropolitan region also has 33 full-service cardio-
vascular surgical centers. To plan for each of these centers
in either Los Angeles or the Dallas–Fort Worth region to of-
fer TAVR would result in the dilution of concentrated expe-
rience. Thus, for a complicated procedure such as TAVR,
which is applied in some of the highest-risk patients treated
for cardiovascular disease, such as those enrolled in the
PARTNER and CoreValve trials, setting up specialized cen-
ters of excellence should be a top consideration for optimiz-
ing patient care and outcomes.
The concept of development of these specialized heart
centers is likely to be somewhat controversial, given the ex-
pectation in the United States that each hospital with expe-
rienced personnel should be able to perform any and all
indicated procedures. However, results of TAVR are likely
to be optimal when performed by a heart team of experi-
enced surgeons, structural interventional cardiologists,
and CV imaging specialists working together in high-
volume tertiary care centers with ancillary support services
capable of dealing with very complex patients with ad-
vanced comorbid conditions. For detailed recommenda-
tions, please refer to the Multisocietal Position Statement
on Operator and Institutional Requirements for TVRR.218
The specific details of the U.S. rollout and reimbursement
for this procedure are as yet to be fully determined. TheThe Journal of Thoracic and Cacriteria for regulatory approval and reimbursement by ap-
propriate federal agencies should be based upon expertise;
high, adjudicated procedure volumes; and documentation
of a health care team approach. In addition, mandatory en-
rollment in structural heart disease registries should be re-
quired so that short- and longer-term outcomes can be
assessed and updated with new evolving data.
8.2. European Perspective
Adoption of TAVR has been rapid, and the changing
trends in Europe have escalated; in selected centers in Ger-
many, TAVR accounts for over 30% of all AVRs. For exam-
ple, 1 single center has an experience of more than 1300
TAVRs and has trained more than 360 doctors in over 32
centers from more than 30 countries. Germany itself has ap-
proximately 87 centers performing TAVR. The miniaturiza-
tion of the applicator device, the option to implant newer
valves from different manufacturers, and the need for
high-quality intraoperative imaging are challenges consis-
tent with the high costs involved with these procedures. Re-
imbursement varies in different countries. In general, at
present, the insurance providers in Europe are bearing the
high costs involved in these operative procedures which
may be questioned in the future, unless outcomes of im-
proved long-term survival are available. The United King-
dom approach to the development of active TAVR centers
has recently been described and can serve as a model for
other countries. This rollout included 2 specific technolo-
gies (ie, Medtronic CoreValve and Edwards Sapien). The
development of this program consisted of didactic session,
simulator training, observation of cases at experienced cen-
ters, and proctoring at new centers. Core essentials of the
program included a multidisciplinary team process for pa-
tient selection and for procedural performance. All patients
undergoing TAVR were entered into a Central Cardiac Au-
dit Database, which included clinical as well as administra-
tive data using standardized data elements and definitions.
This approach has the advantage of including all patients
with either of the 2 devices, monitoring the potential of
changing patient selection criteria, the ability to document
learning curve and the opportunity to evaluate the outcome
of patients treated with each of the devices. Particularly rel-
evant findings include the observation that: (1) 30-day and
mid-term mortality was equivalent in proctored and non-
proctored cases; and (2) the fact that outcomes in the first
20 cases were similar to subsequent cases in each of the
25 centers involved.
9. ROLE OF REGISTRIES
Post-marketing data collection for medical device evalu-
ation is an essential component in the assessment of device
performance and its benefit/risk balance throughout the
product life cycle. In addition to confirmation of datardiovascular Surgery c Volume 144, Number 3 e67
Clinical Guidelines Holmes et alobserved in pre-approval studies, post-marketing studies
provide information regarding ‘real world’ use in patient
subsets not fully tested in pre-market clinical trials. Regis-
tries offer an important platform for post-marketing device
evaluation. For example, the STS National Database and
ACC’s National Cardiovascular Data Registry (NCDR)
that have traditionally focused on national benchmarking,
quality improvement, and research, are rapidly emerging
to fulfill this important role. The ability to link clinical reg-
istry data with administrative data opens an untapped re-
source for monitoring and predicting both short- and
potentially long-term outcomes. In general, the short-term
clinical information can be used for risk stratification and
identification of important clinical subgroups, whereas the
administrative data can be used to track patterns of use
and ultimately long-term events.
In the past, device monitoring has typically been carried
out through industry-supported trials and post-approval
studies. It has been necessary for industry to undertake
the very expensive and time-consuming task of developing
data registries. In the development of these registries, there
has been little coordination with existing societal registries
to harmonize definitions or data specifications. An unfortu-
nate byproduct of this approach has led to the well-
recognized inconsistencies seen in cardiovascular data
reporting. In addition, there is the unavoidable potential
for a conflict of interest that might arise from amanufacturer
conducting studies of its own device.
The use of clinical registries can address many of these
concerns. Registries such as the STS Database and ACC’s
NCDR have a high degree of national participation, so the
data represents a true national experience. These registries
have a well-established protocol for data collection, with
trained abstractors and onsite rigorous audits to ensure
high data quality and completeness of entry. Database def-
initions are generally regarded as national standards, and
there is a high degree of harmonization between terms com-
mon to these registries. These definitions should be based
upon consensus documents; for example, VARC definitions
of stroke.96 Furthermore, each registry can be linked to ad-
ministrative databases in order to obtain long-term outcome
information. These facts demonstrate the ability of the na-
tional cardiovascular registries to serve as the foundation
for comprehensive device registries. In the last few years,
the FDA has collaborated with various organizations to
use registry data to investigate several important device-
related studies. Although there is no specific legislative
mandate to use clinical registries, FDA leadership does
actively encourage the use of registries for device
surveillance.
Registries offer distinct theoretical advantages in this
field, but it should be remembered that practical application
presents unchartered waters. Perhaps 1 major challenge lies
in the fact that a successful program will require closee68 The Journal of Thoracic and Cardiovascular Surgcooperation between multiple organizations. For example,
the STS and ACCF have a long history of cooperation
and collaboration on registry-related projects, holding
monthly conference calls devoted to registry coordination,
thus laying the foundation for collaborative projects such
as device surveillance. Similar collaborations will require
the need for contractual agreements to address issues such
as data ownership, data access, and governance of linked
registries. Sophisticated statistical analysis will be a central
feature of surveillance projects, so coordination with an an-
alytic center will also be necessary. Certainly, FDA input
will be central to any device-related project, and coordina-
tion with the Centers for Medicare and Medicaid Services
(CMS) may be necessary as well. The device manufacturer
will have an essential role, especially in post-approval stud-
ies, so coordination with industry will be a key element of
any project.
Device surveillance will require fundamental changes
in the clinical database operations. Presently, there is no
provision for timely data entry, but post-approval studies
will require exactly that in order to capture adverse events
as they occur. Likewise, post-approval studies require
long-term follow-up of information that cannot be ob-
tained from administrative databases. Provision must be
made to capture information such as echocardiographic
findings and quality-of-life data months to years after de-
vice insertion. It should also be noted that the use of CMS
MedPAR data may have limited usefulness in this context
because of the inability to acquire contemporary data lim-
ited to only those patients>65 years. (In general, the most
current available MedPAR data are 2 years old.) Addi-
tional challenges include standardized rigorous methodol-
ogy adapted for sparse data and standardized reporting
formats modeled after the CONSORT (Consolidated
Standards of Reporting Trials) guidelines for randomized
trials, PRISMA (Preferred Reporting Items for Systematic
reviews and Meta-Analyses) guidelines for meta-analyses,
or STROBE (STrengthening the Reporting of Observa-
tional studies in Epidemiology) guidelines for observational
studies.182,258-260 It should be emphasized that the registry
should capture data on all devices that are placed.
Specific post-approval studies may focus on a smaller,
more select population, but a comprehensive registry
should collect information on all devices for complete anal-
yses independent of industry-sponsored studies. A potential
incentive for participation in the device registry might be
linking it to CMS coverage criteria or other form of federal
legislation.
Funding the device registries requires innovative con-
sideration. Despite the fact that federal agencies encour-
age the use of clinical registries, funding for such
projects is not available for device-related projects. Al-
though industry funding for studies related to their specific
product offers the most straightforward approach otherery c September 2012
TABLE 15. Current treatment recommendations for patients with aortic stenosis
Treatment Indication Major complications
Surgical aortic valve
replacement
 Symptomatic severe AS (Class I, LOE: B)
 Severe AS undergoing CABG, aortic surgery or other
valve surgery (Class I, LOE: C)
 Symptomatic moderate AS undergoing CABG, aortic
surgery or other valve surgery (Class IIa, LOE: C)
 Asymptomatic severe AS with hypotensive response
to exercise (Class IIb; LOE: C)
 Asymptomatic extremely severe AS (AVA<0.6 cm2,
mean gradient>50 mm Hg, or jet velocity>5 m/s)
(Class IIb, LOE: C)
 Mortality (3%)
 Stroke (2%)
 Prolonged ventilation (11%)
 Thromboembolism and bleeding
 Prosthetic dysfunction
 Perioperative complications are higher when surgical
AVR is combined with CABG
Transcatheter aortic
valve replacement
 TAVR is recommended in patients with severe,
symptomatic, calcific stenosis of a trileaflet aortic
valve who have aortic and vascular anatomy suitable
for TAVR and a predicted survival>12 months, and
who have a prohibitive surgical risk as defined by an
estimated 50% or greater risk of mortality or
irreversible morbidity at 30 days or other factors such
as frailty, prior radiation therapy, porcelain aorta, and
severe hepatic or pulmonary disease.
 TAVR is a reasonable alternative to surgical AVR in
patients at high surgical risk (PARTNERTrial Criteria:
STS  8%*)
 Mortality (3% to 5%)
 Stroke (6% to 7%)
 Access complications (17%)
 Pacemaker insertion
B 2% to 9% (Sapien)









Balloon aortic valvuloplasty  Reasonable for palliation in adult patients with AS in
whom surgical AVR cannot be performed because of
serious comorbid conditions (Class IIb, LOE: C)





Medical therapy  No specific therapy for asymptomatic AS
 Medical therapy not indicated for symptomatic severe
AS
 Appropriate control of blood pressure and other risk
factors as indicated
 Statins not indicated for preventing progression of AS
 Diuretics, vasodilators and positive inotropes should
be avoided in patients awaiting surgery because of risk
of destabilization
 Hemodynamic instability
Class I: Conditions for which there is evidence for and/or general agreement that the procedure or treatment is beneficial, useful, and effective; Class II: Conditions for which there
is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment; Class IIa: Weight of evidence/opinion is in favor of usefulness/
efficacy; Class IIb: Usefulness/efficacy is less well established by evidence/opinion; LOE B: Data derived from a single randomized trial or nonrandomized studies; LOE C: Only
consensus opinion of experts, case studies, or standard-of-care. Source of Class/LOE recommendations: Bonow et al.28 AR, Aortic regurgitation; AS, aortic stenosis; AVR, aortic
valve replacement; CABG, coronary artery bypass graft; LOE, level of evidence; STS, Society of Thoracic Surgeons; TAVR, transcatheter aortic valve replacement. *The original
PARTNER protocol specified inclusion criteria as a minimum STS-predicted risk of mortality of 10. During the trial enrollment phase, the minimum STS-predicted risk of
mortality was changed to 8. In both instances, 2 surgeons had to document that the true predicted risk of mortality was 15.
Holmes et al Clinical Guidelinesmodels rely upon centers to pay a fee in return for registry
participation.
As registries are developed, a ‘‘silo’’ construction must
be avoided. It is critically important to keep an eye on the
future so that present plans fit seamlessly with the vision
for future initiatives. This means that a device-specific reg-
istry should be designed to serve as a building block for the
next generation of registries. Planning for interoperability,
resource sharing, and avoidance of duplication will be nec-
essary to create the system of integrated, coordinatedThe Journal of Thoracic and Caregistries that will be the hallmark of registries for the
next decade.10. SUMMARYAND RECOMMENDATIONS
There are a number of potential treatment recommenda-
tions for patients with AS (Table 15). Consideration of the
risk/benefit of each option needs to be carefully evaluated
and discussed with the patient and family. The involvement
of the heart team in decision making is also essential.rdiovascular Surgery c Volume 144, Number 3 e69
Clinical Guidelines Holmes et alThe approval of TAVR represents a fundamental change
in the management of aortic valvular heart disease by offer-
ing an alternative to traditional surgical aortic valve replace-
ment in carefully selected patients. The penetration of this
technology in the broad group of patients with AS remains
to be determined and will depend on the continued evolu-
tion of the technology and the results of clinical trials con-
ducted in these patients. At the present time, several
observations and recommendations can be made.
1. Complex Technology: Although the technique and
equipment continue to evolve, TAVR is a complex pro-
cedure with many interlocking steps that require metic-
ulous attention to achieve optimal results and minimize
complications.
2. Team-Based Approach: A foundational requirement of
TAVR is a team-based approach to patient care. Given
the high-risk profile of patients, who often have multiple
comorbidities, as well as the technical complexity of the
procedure involved, this team-based care will need to in-
clude multiple contributors at different stages in the pro-
cess but will be mainly centered around the primary
cardiologist, the cardiovascular surgeon, and the inter-
ventional cardiologist. Patients and families must be in-
cluded in the care team. Other team members will
include cardiac anesthesiologists, heart failure special-
ists, structural heart disease physicians, imaging special-
ists and the nursing care team, among others.
3. Patient Selection: In adults with severe, symptomatic,
calcific stenosis of a trileaflet aortic valve who have aor-
tic and vascular anatomy suitable for TAVR and a pre-
dicted survival>12 months:
 TAVR is recommended in patients with prohibitive
surgical risk.
 TAVR is a reasonable alternative to surgical AVR in
patients at high surgical risk.
Definitions of severe AS have varied between registries,
trials, and guidelines. In general, all require severely re-
duced, calcified leaflet motion, and aortic jet velocity
>4.0 m/s OR an AVA<1.0 cm2 OR AV index<0.6 cm2/
m2 OR a mean gradient>40 mm Hg. In the setting of LV
systolic dysfunction, severe AS is present when the leaflets
are calcified, with reduced systolic motion, and dobutamine
stress echocardiography shows an aortic velocity of>4.0 m/
s ORmean gradient>40 mmHg with a valve area<1.0 cm2
OR AV index<0.6 cm2/m2 at any flow rate.
Prohibitive surgical risk is defined as:
 An estimated 50% or greater risk of mortality or irre-
versible morbidity at 30 days (as assessed by one car-
diologist and 2 cardiothoracic surgeons), or other
factors such as frailty, prior radiation therapy, porce-
lain aorta, and severe hepatic or pulmonary disease.
 Suitable aortic and vascular anatomy is defined as:e70 The Journal of Thoracic and Cardiovascular Surg Both aortic annulus size and valve plane to coronary os-
tiumheight suitable forplacement of an availableTAVR.
 Adequate vascular access for passage of the TAVR
system (femoral iliac, subclavian, axillary) or suitabil-
ity for an apical implantation approach.
TAVR is not currently recommended because of lim-
ited available information in adults who have:
 An acceptable surgical risk for conventional surgical
AVR
 Known bicuspid aortic valve
 Failing bioprosthetic aortic valve
 Severe mitral annular calcification or severe MR
 Moderate AS
 Other (eg, severe AR and subaortic stenosis)
In these groups, additional scientific data will need to be
collected to ascertain risk/benefit ratio prior to integration
into routine clinical care.
4. TAVR Screening: Screening protocols should be part of
every TAVR evaluation. These may vary from institution
to institution. Some information may be obtained from
referring institutions, whereas some will be obtained
within the institution performing the TAVR. In the for-
mer case, the information obtained must be of high qual-
ity so that optimal recommendations can be formulated.
Requisite pieces of information include:
 Data sufficient to calculate STS score
 Measurement of clinical parameters related to the
presence of comorbid conditions such as pulmonary
function tests in patients with COPD or extent and se-
verity of malignancy if present
 Assessment for the degree of cognitive impairment as
appropriate
 Imaging data to confirm
B Presence and severity o f aortic stenosis
B Presence and severity of associated CAD
B Left ventricular function
B Presence and severity of associated valvular heart
disease lesions
B Presence and extent of cerebral vascular disease
 Preprocedural imaging for planning should be done by
the institution performing TAVR
B Assessment of annular size for device selection
B Assessment of details of arterial anatomy including
the peripheral aortoiliac vessels as well as the aor-
tic arch and ascending aorta which may impact on
access selection
5. Site Selection: Centers should have experience with
structural heart disease. All members of the heart team
should be available onsite. In addition, a structural heart
disease center or clinic, a procedural performance areaery c September 2012
Holmes et al Clinical Guidelines(either a hybrid surgical room or a specially modified
cardiac catheterization laboratory room), a postproce-
dure care team, and expert imaging using echocardiogra-
phy and CT should be available. Setting up specialized
centers of excellence with convenient access to patients
should be a top priority for responsible dissemination of
this technology. For more details, please see facility
requirements in the ‘‘SCAI/AATS/ACCF/STS Multiso-
ciety Expert Consensus Statement: Operator & Institu-
tional Requirements for Transcatheter Valve Repair
and Replacement; Part 1 TAVR.’’218
6. Center and Physician Experience: Expertise with surgi-
cal AVR is essential—the number of surgical proce-
dures has been recommended to be 50 within the past
12 months. For the interventional cardiologist, experi-
ence with balloon aortic valvuloplasty as well as expe-
rience in a team-based care approach is recommended.
During the rollout of the procedure, experienced proc-
tors will form part of the heart care team. These physi-
cians will be onsite for the first several cases after a site
has been initiated. After the performance of these initial
procedures, centers will be eligible to qualify for inde-
pendent TAVR. Physician teams need to be experienced
with transapical, transarterial, and alternative arterial
approaches for TAVR. For detailed information on re-
quirements for interventional cardiologists and sur-
geons to perform TAVR, please refer to the ‘‘SCAI/
AATS/ACCF/STS Multisociety Expert Consensus
Statement: Operator & Institutional Requirements for
Transcatheter Valve Repair and Replacement; Part 1
TAVR.’’218
7. Procedural Performance: TAVR should be performed in
either specially modified, large cardiac catheterization
laboratories or hybrid rooms. Fixed imaging and intra-
procedural echocardiography are required as are capa-
bilities for cardiopulmonary bypass for management of
procedural complications. In addition to the valve im-
plantation equipment, peripheral and coronary interven-
tions equipment must be available for urgent treatment
of complications. The ability to provide general anesthe-
sia should be available.
8. Postprocedural Care: The intensity of postprocedural
care depends on the presence of comorbidities, as well
as the results of the TAVR itself. Protocols should be de-
fined for routine care, as well as management of specific
problems and complications. Ideally, a dedicated recov-
ery area should be established at each site to which all
patients should be transferred for optimal postprocedural
care. Postdischarge care plans should include consider-
ation of rehabilitation, and home health or other support
needed during recovery. In addition, follow-up with the
primary care team can ensure successful transitions of
care.The Journal of Thoracic and Ca9. Registries: Participation is recommended in national
TAVR registries that include clinical and administrative
claims data that will allow careful evaluation of both
short-term and long-term risks and benefits and track
changes in patient selection criteria, procedural perfor-
mance, and device iteration. Preferably, registries should
also capture demographics and mortality outcome data
of surgically and medically treated patients in order to
facilitate comparison of different therapeutic strategies
to improve identification and selection of optimal thera-
peutic options.98-104
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